[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$friHxoVxnScPyHl4CJdgXmpbLSY5uGBoEWuaYivgBVaA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"Merck KGaA, Darmstadt, Germany",[4],275,false,0,42,85269,65,[13,16,19,22,25,28,31,33],{"name":14,"count":15},"Infertility",29,{"name":17,"count":18},"Multiple Sclerosis",23,{"name":20,"count":21},"Healthy",21,{"name":23,"count":24},"Growth Disorders",20,{"name":26,"count":27},"Multiple Sclerosis, Relapsing-Remitting",11,{"name":29,"count":30},"Hypertension",9,{"name":32,"count":30},"Ovulation Induction",{"name":34,"count":35},"Solid Tumors",5,[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,139,194,241,285,318,355,389,425,447,481,517,544,562,585,613,631,649,667,685,703,728,752,776,794,821,839,865,883,906,931,949,973,991,1016,1040,1067,1085,1103,1121,1246,1305,1367,1408,1449,1492,1537,1568,1595,1617,1655,1682,1715,1737,1774,1806,1832,1850,1868,1886,1904,1926,1952,1970,1988,2006,2031,2049,2073,2102,2120,2144,2162,2186,2204,2230,2248,2266,2284,2310,2328,2351,2369,2391,2415,2433,2451,2477,2495,2513,2531,2549,2567,2636,2668,2702,2724,2746,2779,2802,2820,2838,2856,2874,2892,2910,2928,2951,2975,2993,3018,3036,3054,3072,3090,3108,3126,3144,3162,3180,3205,3223,3241,3259,3285,3303,3321,3339,3365,3383,3401,3419,3437,3455,3481,3499,3524,3542,3560,3578,3596,3614,3632,3650,3668,3693,3711,3729,3747,3765,3783,3801,3819,3842,3860,3895,3926,3961,3995,4026,4059,4091,4122,4155,4177,4198,4221,4239,4257,4281,4304,4327,4345,4370,4388,4406,4429,4447,4465,4483,4507,4525,4547,4569,4592,4610,4634,4652,4670,4688,4711,4736,4760,4784,4802,4825,4848,4866,4889,4907,4930,4948,4966,4989,5014,5032,5050,5078,5096,5114,5132,5159,5177,5195,5216,5238,5256,5274,5292,5317,5335,5456,5519,5564,5626,5687,5720,5751,5784,5813,5842,5868,5890,5917,5939,5961,5979,6001,6024,6046,6071,6093,6114,6137,6161],{"intervention":46,"totalTrials":47,"cells":48},"Bisoprolol",8,{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":65,"PHASE3":67,"PHASE4":69,"NA":137},{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":62},"NCT03226275","Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants","COMPLETED",[39],"2017-09-09","2017-08-09",32,[20],[63,46,64],"Bisoprolol-Amlodipine FDC","Amlodipine",{"trials":66,"activeCount":8},[],{"trials":68,"activeCount":8},[],{"trials":70,"activeCount":8},[71,81,89,99,108,117,127],{"nctId":72,"briefTitle":73,"status":56,"phases":74,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT01079962","An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])",[42],"2011-10","2009-12",209,[29],[46,80],"Atenolol",{"nctId":82,"briefTitle":83,"status":56,"phases":84,"primaryCompletion":85,"completion":85,"start":76,"enrollment":86,"conditions":87,"interventions":88},"NCT01190436","A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes",[42],"2011-12",125,[29],[46],{"nctId":90,"briefTitle":91,"status":56,"phases":92,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"NCT01104558","Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.",[42],"2010-07","2008-12",100,[97],"Chronic Heart Failure",[46],{"nctId":100,"briefTitle":101,"status":56,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":107},"NCT01251146","A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension",[42],"2012-02","2010-11",177,[29],[46,80],{"nctId":109,"briefTitle":110,"status":56,"phases":111,"primaryCompletion":112,"completion":112,"start":85,"enrollment":113,"conditions":114,"interventions":115},"NCT01508325","Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients",[42],"2014-04",186,[29],[46,116],"Metoprolol",{"nctId":118,"briefTitle":119,"status":56,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT01066039","Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control",[42],"2013-04","2010-04",202,[29,125],"Diabetes Mellitus, Type II",[46],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":24,"conditions":134,"interventions":136},"NCT03026088","Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants","TERMINATED",[42],"2018-12-26","2017-03-21",[135],"Heart Failure",[46],{"trials":138,"activeCount":8},[],{"intervention":140,"totalTrials":141,"cells":142},"Rebif®",4,{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":161,"NA":192},{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[],{"trials":148,"activeCount":8},[],{"trials":150,"activeCount":8},[151],{"nctId":152,"briefTitle":153,"status":56,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT00287079","A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome",[41],"2008-11","2005-10",35,[159],"Clinically Isolated Syndrome",[140],{"trials":162,"activeCount":8},[163,173,183],{"nctId":164,"briefTitle":165,"status":56,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT00367484","Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis",[42],"2006-01","2004-05",460,[171],"Relapsing Remitting Multiple Sclerosis",[140],{"nctId":174,"briefTitle":175,"status":56,"phases":176,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT01791244","A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device",[42],"2016-02-29","2013-02-28",93,[17,181],"Relapsing-Remitting",[140],{"nctId":184,"briefTitle":185,"status":56,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT02064816","A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis",[42],"2016-04-30","2014-05-31",200,[26],[140,140],{"trials":193,"activeCount":8},[],{"intervention":195,"totalTrials":196,"cells":197},"Recombinant human growth hormone",3,{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":214,"PHASE4":226,"NA":239},{"trials":199,"activeCount":8},[],{"trials":201,"activeCount":8},[],{"trials":203,"activeCount":8},[204],{"nctId":205,"briefTitle":206,"status":56,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT01111019","Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children",[40],"2017-01-17","2006-03-21",19,[212],"Hypochondroplasia",[195],{"trials":215,"activeCount":8},[216],{"nctId":217,"briefTitle":218,"status":130,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT01067352","A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)",[41],"2009-07","2004-02",25,[224],"Infant, Small for Gestational Age",[195],{"trials":227,"activeCount":8},[228],{"nctId":229,"briefTitle":230,"status":56,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT01187550","Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®",[42],"2008-09","2009-04","2007-03",214,[237],"Dwarfism, Pituitary",[195],{"trials":240,"activeCount":8},[],{"intervention":242,"totalTrials":196,"cells":243},"Efalizumab",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":261,"NA":283},{"trials":245,"activeCount":8},[],{"trials":247,"activeCount":8},[],{"trials":249,"activeCount":8},[],{"trials":251,"activeCount":8},[252],{"nctId":253,"briefTitle":254,"status":56,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"conditions":258,"interventions":260},"NCT00442650","Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis",[41],"2005-12","2004-01",[259],"Moderate to Severe Psoriasis",[242],{"trials":262,"activeCount":8},[263,274],{"nctId":264,"briefTitle":265,"status":56,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":273},"NCT00287118","A Multicentre, Open Label Phase IIIb\u002FIV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis",[42],"2006-05-30","2004-10-27",189,[271,272],"Candidates for Systemic Therapy for Psoriasis","Psoriasis",[242],{"nctId":275,"briefTitle":276,"status":130,"phases":277,"primaryCompletion":278,"start":232,"enrollment":279,"conditions":280,"interventions":282},"NCT00972543","Raptiva in Palm and Sole Psoriasis",[42],"2009-05",6,[281],"Chronic Plaque Psoriasis",[242],{"trials":284,"activeCount":8},[],{"intervention":286,"totalTrials":287,"cells":288},"Efalizumab - anti CD11a recombinant human monoclonal antibody",2,{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":316},{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[],{"trials":294,"activeCount":8},[],{"trials":296,"activeCount":8},[],{"trials":298,"activeCount":8},[299,307],{"nctId":300,"briefTitle":301,"status":130,"phases":302,"primaryCompletion":233,"completion":233,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT00697593","ChangE From Any Systemic psoriasiS therapY to Raptiva",[42],"2008-01",70,[281],[286],{"nctId":308,"briefTitle":309,"status":130,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":315},"NCT00739882","TRUST Study: Raptiva ® in Hand & Foot Psoriasis",[42],"2009-06","2008-04",76,[281],[286],{"trials":317,"activeCount":8},[],{"intervention":319,"totalTrials":287,"cells":320},"r-hGH",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":353},{"trials":322,"activeCount":8},[],{"trials":324,"activeCount":8},[],{"trials":326,"activeCount":8},[],{"trials":328,"activeCount":8},[],{"trials":330,"activeCount":8},[331,342],{"nctId":332,"briefTitle":333,"status":56,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":341},"NCT01157793","A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood",[42],"2005-02","2003-09",34,[339,340],"Dwarfism","Growth Hormone Deficiency",[319,319],{"nctId":343,"briefTitle":344,"status":56,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT01066052","Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years",[42],"1999-03-31","2010-08-31","1992-02-29",115,[351],"Turner's Syndrome",[319],{"trials":354,"activeCount":8},[],{"intervention":356,"totalTrials":287,"cells":357},"Kuvan®",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":376,"NA":387},{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[],{"trials":363,"activeCount":8},[],{"trials":365,"activeCount":8},[366],{"nctId":367,"briefTitle":368,"status":56,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT01732471","Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria",[41],"2013-10","2012-11",90,[374],"Phenylketonuria",[356],{"trials":377,"activeCount":8},[378],{"nctId":379,"briefTitle":380,"status":56,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT01082328","Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period",[42],"2012-05","2010-05",59,[374],[356],{"trials":388,"activeCount":8},[],{"intervention":390,"totalTrials":287,"cells":391},"Recombinant human chorionic gonadotrophin",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":411,"NA":423},{"trials":393,"activeCount":8},[],{"trials":395,"activeCount":8},[],{"trials":397,"activeCount":8},[],{"trials":399,"activeCount":8},[400],{"nctId":401,"briefTitle":402,"status":56,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT02047227","Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)",[41],"2015-08-31","2014-01-31",939,[14],[409,410,390],"Pergoveris®","GONAL-f®",{"trials":412,"activeCount":8},[413],{"nctId":414,"briefTitle":415,"status":56,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT00249834","Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)",[42],"2006-01-16","2004-09-22",166,[14],[422,390],"Gonal-f",{"trials":424,"activeCount":8},[],{"intervention":80,"totalTrials":287,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":445},{"trials":428,"activeCount":8},[],{"trials":430,"activeCount":8},[],{"trials":432,"activeCount":8},[],{"trials":434,"activeCount":8},[],{"trials":436,"activeCount":8},[437,441],{"nctId":72,"briefTitle":73,"status":56,"phases":438,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":439,"interventions":440},[42],[29],[46,80],{"nctId":100,"briefTitle":101,"status":56,"phases":442,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":443,"interventions":444},[42],[29],[46,80],{"trials":446,"activeCount":8},[],{"intervention":448,"totalTrials":287,"cells":449},"Mavenclad®",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":479},{"trials":451,"activeCount":8},[],{"trials":453,"activeCount":8},[],{"trials":455,"activeCount":8},[],{"trials":457,"activeCount":8},[],{"trials":459,"activeCount":8},[460,469],{"nctId":461,"briefTitle":462,"status":56,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":468},"NCT03369665","Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)",[42],"2021-11-12","2018-06-20",485,[17],[448],{"nctId":470,"briefTitle":471,"status":56,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":478},"NCT03364036","Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)",[42],"2020-05-05","2022-02-21","2018-05-28",270,[17],[448],{"trials":480,"activeCount":8},[],{"intervention":482,"totalTrials":287,"cells":483},"Nicorandil",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":515},{"trials":485,"activeCount":8},[],{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[],{"trials":491,"activeCount":8},[],{"trials":493,"activeCount":8},[494,506],{"nctId":495,"briefTitle":496,"status":56,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":504},"NCT01396395","Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina",[42],"2014-05","2011-09",402,[502,503],"Stable Angina","Coronary Disease",[482,505],"Standard Treatment",{"nctId":507,"briefTitle":508,"status":130,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":47,"conditions":512,"interventions":514},"NCT03010423","Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants",[42],"2019-07-09","2016-11-30",[513],"Non-obstructive Coronary Artery Disease",[482],{"trials":516,"activeCount":8},[],{"intervention":518,"totalTrials":519,"cells":520},"Gabapentin\u002FB-complex",1,{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":542},{"trials":522,"activeCount":8},[],{"trials":524,"activeCount":8},[],{"trials":526,"activeCount":8},[],{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[531],{"nctId":532,"briefTitle":533,"status":56,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01364298","Efficacy and Safety of Gabapentin\u002FB-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management",[42],"2012-07","2011-04",353,[539],"Diabetic Peripheral Neuropathic Pain",[518,541],"Pregabalin",{"trials":543,"activeCount":8},[],{"intervention":541,"totalTrials":519,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":560},{"trials":547,"activeCount":8},[],{"trials":549,"activeCount":8},[],{"trials":551,"activeCount":8},[],{"trials":553,"activeCount":8},[],{"trials":555,"activeCount":8},[556],{"nctId":532,"briefTitle":533,"status":56,"phases":557,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":558,"interventions":559},[42],[539],[518,541],{"trials":561,"activeCount":8},[],{"intervention":563,"totalTrials":519,"cells":564},"GONAL f® prefilled pen",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":583},{"trials":566,"activeCount":8},[],{"trials":568,"activeCount":8},[],{"trials":570,"activeCount":8},[],{"trials":572,"activeCount":8},[],{"trials":574,"activeCount":8},[575],{"nctId":576,"briefTitle":577,"status":56,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":189,"conditions":581,"interventions":582},"NCT00829244","CONSORT Randomized Controlled Trial in Assisted Reproductive Technology",[42],"2010-01","2008-08",[14],[563,563],{"trials":584,"activeCount":8},[],{"intervention":586,"totalTrials":519,"cells":587},"Cyclosporins",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":611},{"trials":589,"activeCount":8},[],{"trials":591,"activeCount":8},[],{"trials":593,"activeCount":8},[],{"trials":595,"activeCount":8},[],{"trials":597,"activeCount":8},[598],{"nctId":599,"briefTitle":600,"status":56,"phases":601,"primaryCompletion":602,"completion":603,"start":221,"enrollment":604,"conditions":605,"interventions":606},"NCT01079988","Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence",[42],"2004-12","2005-04",41,[272],[586,607,608,609,610],"Retinoids","Systemic corticosteroids","Methotrexate","Systemic corticosteroids\u002Fmethotrexate",{"trials":612,"activeCount":8},[],{"intervention":607,"totalTrials":519,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":629},{"trials":616,"activeCount":8},[],{"trials":618,"activeCount":8},[],{"trials":620,"activeCount":8},[],{"trials":622,"activeCount":8},[],{"trials":624,"activeCount":8},[625],{"nctId":599,"briefTitle":600,"status":56,"phases":626,"primaryCompletion":602,"completion":603,"start":221,"enrollment":604,"conditions":627,"interventions":628},[42],[272],[586,607,608,609,610],{"trials":630,"activeCount":8},[],{"intervention":608,"totalTrials":519,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":647},{"trials":634,"activeCount":8},[],{"trials":636,"activeCount":8},[],{"trials":638,"activeCount":8},[],{"trials":640,"activeCount":8},[],{"trials":642,"activeCount":8},[643],{"nctId":599,"briefTitle":600,"status":56,"phases":644,"primaryCompletion":602,"completion":603,"start":221,"enrollment":604,"conditions":645,"interventions":646},[42],[272],[586,607,608,609,610],{"trials":648,"activeCount":8},[],{"intervention":609,"totalTrials":519,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":665},{"trials":652,"activeCount":8},[],{"trials":654,"activeCount":8},[],{"trials":656,"activeCount":8},[],{"trials":658,"activeCount":8},[],{"trials":660,"activeCount":8},[661],{"nctId":599,"briefTitle":600,"status":56,"phases":662,"primaryCompletion":602,"completion":603,"start":221,"enrollment":604,"conditions":663,"interventions":664},[42],[272],[586,607,608,609,610],{"trials":666,"activeCount":8},[],{"intervention":610,"totalTrials":519,"cells":668},{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":683},{"trials":670,"activeCount":8},[],{"trials":672,"activeCount":8},[],{"trials":674,"activeCount":8},[],{"trials":676,"activeCount":8},[],{"trials":678,"activeCount":8},[679],{"nctId":599,"briefTitle":600,"status":56,"phases":680,"primaryCompletion":602,"completion":603,"start":221,"enrollment":604,"conditions":681,"interventions":682},[42],[272],[586,607,608,609,610],{"trials":684,"activeCount":8},[],{"intervention":116,"totalTrials":519,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":701},{"trials":688,"activeCount":8},[],{"trials":690,"activeCount":8},[],{"trials":692,"activeCount":8},[],{"trials":694,"activeCount":8},[],{"trials":696,"activeCount":8},[697],{"nctId":109,"briefTitle":110,"status":56,"phases":698,"primaryCompletion":112,"completion":112,"start":85,"enrollment":113,"conditions":699,"interventions":700},[42],[29],[46,116],{"trials":702,"activeCount":8},[],{"intervention":704,"totalTrials":519,"cells":705},"Saizen® solution for",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":726},{"trials":707,"activeCount":8},[],{"trials":709,"activeCount":8},[],{"trials":711,"activeCount":8},[],{"trials":713,"activeCount":8},[],{"trials":715,"activeCount":8},[716],{"nctId":717,"briefTitle":718,"status":56,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT01806298","An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)",[42],"2016-03","2013-06",78,[724],"Adult Growth Hormone Deficiency",[704],{"trials":727,"activeCount":8},[],{"intervention":729,"totalTrials":519,"cells":730},"Recombinant FSH",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":750},{"trials":732,"activeCount":8},[],{"trials":734,"activeCount":8},[],{"trials":736,"activeCount":8},[],{"trials":738,"activeCount":8},[],{"trials":740,"activeCount":8},[741],{"nctId":742,"briefTitle":743,"status":56,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT01081626","Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction",[42],"2011-03","2009-03",310,[32],[729],{"trials":751,"activeCount":8},[],{"intervention":753,"totalTrials":519,"cells":754},"Glucophage",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":774},{"trials":756,"activeCount":8},[],{"trials":758,"activeCount":8},[],{"trials":760,"activeCount":8},[],{"trials":762,"activeCount":8},[],{"trials":764,"activeCount":8},[765],{"nctId":766,"briefTitle":767,"status":768,"phases":769,"primaryCompletion":770,"start":770,"enrollment":8,"conditions":771,"interventions":773},"NCT01510522","Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets","WITHDRAWN",[42],"2012-06",[772],"Diabetes Mellitus Type 2",[753,753],{"trials":775,"activeCount":8},[],{"intervention":505,"totalTrials":519,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":792},{"trials":779,"activeCount":8},[],{"trials":781,"activeCount":8},[],{"trials":783,"activeCount":8},[],{"trials":785,"activeCount":8},[],{"trials":787,"activeCount":8},[788],{"nctId":495,"briefTitle":496,"status":56,"phases":789,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":790,"interventions":791},[42],[502,503],[482,505],{"trials":793,"activeCount":8},[],{"intervention":795,"totalTrials":519,"cells":796},"Metformin IR",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":819},{"trials":798,"activeCount":8},[],{"trials":800,"activeCount":8},[],{"trials":802,"activeCount":8},[],{"trials":804,"activeCount":8},[],{"trials":806,"activeCount":8},[807],{"nctId":808,"briefTitle":809,"status":56,"phases":810,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":817},"NCT02252965","Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes",[42],"2015-11","2016-04","2014-12",532,[816],"Diabetes Mellitus, Type 2",[795,818],"Metformin XR",{"trials":820,"activeCount":8},[],{"intervention":818,"totalTrials":519,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":837},{"trials":824,"activeCount":8},[],{"trials":826,"activeCount":8},[],{"trials":828,"activeCount":8},[],{"trials":830,"activeCount":8},[],{"trials":832,"activeCount":8},[833],{"nctId":808,"briefTitle":809,"status":56,"phases":834,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":835,"interventions":836},[42],[816],[795,818],{"trials":838,"activeCount":8},[],{"intervention":840,"totalTrials":519,"cells":841},"Low Dose Bisoprolol",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":863},{"trials":843,"activeCount":8},[],{"trials":845,"activeCount":8},[],{"trials":847,"activeCount":8},[],{"trials":849,"activeCount":8},[],{"trials":851,"activeCount":8},[852],{"nctId":853,"briefTitle":854,"status":56,"phases":855,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":861},"NCT01074307","A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea",[42],"2012-08","2009-10",180,[860],"Heart Failure, Congestive",[840,862],"High Dose Bisoprolol",{"trials":864,"activeCount":8},[],{"intervention":862,"totalTrials":519,"cells":866},{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":881},{"trials":868,"activeCount":8},[],{"trials":870,"activeCount":8},[],{"trials":872,"activeCount":8},[],{"trials":874,"activeCount":8},[],{"trials":876,"activeCount":8},[877],{"nctId":853,"briefTitle":854,"status":56,"phases":878,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":879,"interventions":880},[42],[860],[840,862],{"trials":882,"activeCount":8},[],{"intervention":884,"totalTrials":519,"cells":885},"Sigmart",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":904},{"trials":887,"activeCount":8},[],{"trials":889,"activeCount":8},[],{"trials":891,"activeCount":8},[],{"trials":893,"activeCount":8},[],{"trials":895,"activeCount":8},[896],{"nctId":897,"briefTitle":898,"status":768,"phases":899,"primaryCompletion":900,"start":900,"enrollment":8,"conditions":901,"interventions":903},"NCT01185015","A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization",[42],"2011-01",[902],"Angina Pectoris",[884],{"trials":905,"activeCount":8},[],{"intervention":907,"totalTrials":519,"cells":908},"Crinone",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":917,"NA":929},{"trials":910,"activeCount":8},[],{"trials":912,"activeCount":8},[],{"trials":914,"activeCount":8},[],{"trials":916,"activeCount":8},[],{"trials":918,"activeCount":8},[919],{"nctId":920,"briefTitle":921,"status":130,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":927},"NCT03858049","Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)",[42],"2021-10-27","2019-05-31",172,[14],[907,928],"Duphaston",{"trials":930,"activeCount":8},[],{"intervention":928,"totalTrials":519,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":947},{"trials":934,"activeCount":8},[],{"trials":936,"activeCount":8},[],{"trials":938,"activeCount":8},[],{"trials":940,"activeCount":8},[],{"trials":942,"activeCount":8},[943],{"nctId":920,"briefTitle":921,"status":130,"phases":944,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":945,"interventions":946},[42],[14],[907,928],{"trials":948,"activeCount":8},[],{"intervention":950,"totalTrials":519,"cells":951},"Colposeptine",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":971},{"trials":953,"activeCount":8},[],{"trials":955,"activeCount":8},[],{"trials":957,"activeCount":8},[],{"trials":959,"activeCount":8},[],{"trials":961,"activeCount":8},[962],{"nctId":963,"briefTitle":964,"status":130,"phases":965,"primaryCompletion":104,"completion":104,"start":93,"enrollment":966,"conditions":967,"interventions":969},"NCT01153958","Colposeptine for the Treatment of Bacterial Vaginosis",[42],133,[968],"Vaginosis, Bacterial",[950,970],"Metronidazole",{"trials":972,"activeCount":8},[],{"intervention":970,"totalTrials":519,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":989},{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[],{"trials":980,"activeCount":8},[],{"trials":982,"activeCount":8},[],{"trials":984,"activeCount":8},[985],{"nctId":963,"briefTitle":964,"status":130,"phases":986,"primaryCompletion":104,"completion":104,"start":93,"enrollment":966,"conditions":987,"interventions":988},[42],[968],[950,970],{"trials":990,"activeCount":8},[],{"intervention":992,"totalTrials":519,"cells":993},"Saizen",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1014},{"trials":995,"activeCount":8},[],{"trials":997,"activeCount":8},[],{"trials":999,"activeCount":8},[],{"trials":1001,"activeCount":8},[],{"trials":1003,"activeCount":8},[1004],{"nctId":1005,"briefTitle":1006,"status":56,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},"NCT00256126","Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®",[42],"2007-09-30","2005-05-31",318,[340,1012],"Turner Syndrome",[992,992],{"trials":1015,"activeCount":8},[],{"intervention":1017,"totalTrials":519,"cells":1018},"Efalizumab - anti-CD11a recombinant human monoclonal antibody",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1027,"NA":1038},{"trials":1020,"activeCount":8},[],{"trials":1022,"activeCount":8},[],{"trials":1024,"activeCount":8},[],{"trials":1026,"activeCount":8},[],{"trials":1028,"activeCount":8},[1029],{"nctId":1030,"briefTitle":1031,"status":56,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1037},"NCT00249808","A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies",[42],"2007-01-25","2004-12-13",1266,[272],[1017],{"trials":1039,"activeCount":8},[],{"intervention":1041,"totalTrials":519,"cells":1042},"Gonal -f® [r-hFSH]",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1065},{"trials":1044,"activeCount":8},[],{"trials":1046,"activeCount":8},[],{"trials":1048,"activeCount":8},[],{"trials":1050,"activeCount":8},[],{"trials":1052,"activeCount":8},[1053],{"nctId":1054,"briefTitle":1055,"status":130,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":580,"enrollment":1058,"conditions":1059,"interventions":1061},"NCT01210144","EXpression PRofile Endometrium Samples Study",[42],"2010-08",27,[1060],"In Vitro Fertilization",[1041,1062,1063,1064],"Ovitrelle® [r-hCG alfa]","Gonadotropin-releasing hormone (GnRH) Agonist","Gonadotropin-releasing hormone (GnRH) Antagonist",{"trials":1066,"activeCount":8},[],{"intervention":1062,"totalTrials":519,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1083},{"trials":1070,"activeCount":8},[],{"trials":1072,"activeCount":8},[],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[],{"trials":1078,"activeCount":8},[1079],{"nctId":1054,"briefTitle":1055,"status":130,"phases":1080,"primaryCompletion":1057,"completion":1057,"start":580,"enrollment":1058,"conditions":1081,"interventions":1082},[42],[1060],[1041,1062,1063,1064],{"trials":1084,"activeCount":8},[],{"intervention":1063,"totalTrials":519,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1101},{"trials":1088,"activeCount":8},[],{"trials":1090,"activeCount":8},[],{"trials":1092,"activeCount":8},[],{"trials":1094,"activeCount":8},[],{"trials":1096,"activeCount":8},[1097],{"nctId":1054,"briefTitle":1055,"status":130,"phases":1098,"primaryCompletion":1057,"completion":1057,"start":580,"enrollment":1058,"conditions":1099,"interventions":1100},[42],[1060],[1041,1062,1063,1064],{"trials":1102,"activeCount":8},[],{"intervention":1064,"totalTrials":519,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1119},{"trials":1106,"activeCount":8},[],{"trials":1108,"activeCount":8},[],{"trials":1110,"activeCount":8},[],{"trials":1112,"activeCount":8},[],{"trials":1114,"activeCount":8},[1115],{"nctId":1054,"briefTitle":1055,"status":130,"phases":1116,"primaryCompletion":1057,"completion":1057,"start":580,"enrollment":1058,"conditions":1117,"interventions":1118},[42],[1060],[1041,1062,1063,1064],{"trials":1120,"activeCount":8},[],{"intervention":1122,"totalTrials":30,"cells":1123},"Cisplatin",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1221,"PHASE4":1242,"NA":1244},{"trials":1125,"activeCount":8},[],{"trials":1127,"activeCount":8},[],{"trials":1129,"activeCount":8},[1130,1143,1155,1169,1182,1196,1211],{"nctId":1131,"briefTitle":1132,"status":56,"phases":1133,"primaryCompletion":499,"completion":721,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT00705016","Cilengitide in Recurrent and\u002For Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[39,40],"2008-10",184,[1137],"Squamous Cell Cancer",[1139,1140,1141,1142,1122],"Cilengitide 2000 mg once weekly","Cilengitide 2000 mg twice weekly","Cetuximab","5-fluorouracil",{"nctId":1144,"briefTitle":1145,"status":56,"phases":1146,"primaryCompletion":220,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT00463788","Cetuximab and Cisplatin in the Treatment of \"Triple Negative\" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer",[40],"2011-02","2007-06",181,[1151],"Breast Neoplasm",[1153,1154],"cetuximab, cisplatin","cisplatin",{"nctId":1156,"briefTitle":1157,"status":56,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1164},"NCT00842712","Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)",[40],"2013-07","2009-02",232,[1163],"Carcinoma, Non-Small-Cell Lung",[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],"Cilengitide","Gemcitabine","Vinorelbine","Chemotherapy",{"nctId":1170,"briefTitle":1171,"status":56,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT03717155","Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC",[40],"2020-09-30","2021-05-27","2018-10-30",43,[1178],"Squamous Non-Small Cell Lung Cancer",[1180,1141,1166,1122,1181],"Avelumab","Carboplatin",{"nctId":1183,"briefTitle":1184,"status":56,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT01982955","Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)",[39,40],"2017-12-12","2021-10-14","2013-12-23",88,[1191],"Non-small Cell Lung Cancer",[1193,1194,1195,1122,1181],"Tepotinib","Gefitinib","Pemetrexed",{"nctId":1197,"briefTitle":1198,"status":56,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1207},"NCT00215644","Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer",[40],"2008-07-31","2008-08-31","2005-08-31",72,[1205,1206],"Esophageal Cancer","Gastric Cancer",[1208,1209,1122,1210],"Matuzumab","Epirubicin","Capecitabine",{"nctId":1212,"briefTitle":1213,"status":56,"phases":1214,"primaryCompletion":856,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1219},"NCT01388790","Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer",[40],"2013-05","2011-06",40,[1206],[1141,1122,1220],"S-1",{"trials":1222,"activeCount":8},[1223,1232],{"nctId":1224,"briefTitle":1225,"status":56,"phases":1226,"primaryCompletion":900,"completion":371,"start":76,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT01177956","A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and\u002For Metastatic Squamous Cell Carcinoma in Head and Neck",[41],73,[1229],"Squamous Cell Carcinoma of the Head and Neck",[1141,1122,1231],"5-Fluorouracil",{"nctId":1233,"briefTitle":1234,"status":56,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1241},"NCT00678535","Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer",[41],"2012-03","2013-02","2008-06",904,[1206],[1141,1210,1122],{"trials":1243,"activeCount":8},[],{"trials":1245,"activeCount":8},[],{"intervention":1247,"totalTrials":35,"cells":1248},"Single low dose cyclophosphamide",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1291,"PHASE4":1301,"NA":1303},{"trials":1250,"activeCount":8},[],{"trials":1252,"activeCount":8},[],{"trials":1254,"activeCount":8},[1255,1266,1275,1283],{"nctId":1256,"briefTitle":1257,"status":56,"phases":1258,"primaryCompletion":1259,"completion":535,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT00157209","Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)",[40],"2006-03","2000-08",171,[1263,1163],"Lung Neoplasms",[1265,1247],"Tecemotide",{"nctId":1267,"briefTitle":1268,"status":56,"phases":1269,"primaryCompletion":1270,"completion":1271,"start":603,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT00157196","Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease",[40],"2007-09","2012-04",22,[1163,1263],[1265,1247],{"nctId":1276,"briefTitle":1277,"status":56,"phases":1278,"primaryCompletion":498,"completion":1279,"start":94,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT00960115","Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy",[39,40],"2015-06",178,[1191],[1265,1247],{"nctId":1284,"briefTitle":1285,"status":56,"phases":1286,"primaryCompletion":1147,"completion":1236,"start":303,"enrollment":337,"conditions":1287,"interventions":1289},"NCT01094548","Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy",[40],[1288],"Multiple Myeloma",[1265,1265,1247,1290],"Multiple low dose cyclophosphamide",{"trials":1292,"activeCount":8},[1293],{"nctId":1294,"briefTitle":1295,"status":130,"phases":1296,"primaryCompletion":1279,"completion":1279,"start":76,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT01015443","Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population",[41],285,[1299],"Non-Small Cell Lung Cancer",[1265,1247],{"trials":1302,"activeCount":8},[],{"trials":1304,"activeCount":8},[],{"intervention":1306,"totalTrials":141,"cells":1307},"Recombinant human chorionic gonadotropin",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1339,"PHASE4":1363,"NA":1365},{"trials":1309,"activeCount":8},[],{"trials":1311,"activeCount":8},[],{"trials":1313,"activeCount":8},[1314,1327],{"nctId":1315,"briefTitle":1316,"status":130,"phases":1317,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT00553514","AS900672-Enriched in Ovulation Induction",[40],"2007-12",71,[32],[1322,1323,1324,1325,1326,1306],"AS900672-Enriched 10 microgram","AS900672-Enriched 20 mcg","AS900672-Enriched 30 mcg","AS900672-Enriched 40 mcg","Follitropin alfa 75 international unit",{"nctId":1328,"briefTitle":1329,"status":56,"phases":1330,"primaryCompletion":232,"completion":232,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1334},"NCT00505752","Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)",[40],"2007-01",520,[14],[1335,1336,1337,1338,1306],"AS900672-Enriched 50 microgram","AS900672-Enriched 100 mcg","AS900672-Enriched 150 mcg","Follitropin alfa 150 international unit",{"trials":1340,"activeCount":8},[1341,1352],{"nctId":1342,"briefTitle":1343,"status":56,"phases":1344,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":123,"conditions":1347,"interventions":1350},"NCT01297465","PERgoveriS In Stratified Treatment for Assisted Reproductive Technique",[41],"2012-10-31","2011-05-31",[1348,1349],"Assisted Reproductive Techniques","Reproductive Technology, Assisted",[1351,409,409,1306],"Gonal-f®",{"nctId":1353,"briefTitle":1354,"status":130,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":382,"enrollment":1357,"conditions":1358,"interventions":1361},"NCT01497197","A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique",[41],"2014-01",174,[14,1359,1360],"Fertility","Follicle Stimulating Hormone Deficiency",[410,1362,1306],"Luveris®",{"trials":1364,"activeCount":8},[],{"trials":1366,"activeCount":8},[],{"intervention":1142,"totalTrials":141,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1387,"PHASE4":1404,"NA":1406},{"trials":1370,"activeCount":8},[],{"trials":1372,"activeCount":8},[],{"trials":1374,"activeCount":8},[1375,1379],{"nctId":1131,"briefTitle":1132,"status":56,"phases":1376,"primaryCompletion":499,"completion":721,"start":1134,"enrollment":1135,"conditions":1377,"interventions":1378},[39,40],[1137],[1139,1140,1141,1142,1122],{"nctId":1380,"briefTitle":1381,"status":56,"phases":1382,"primaryCompletion":745,"start":220,"enrollment":1383,"conditions":1384,"interventions":1385},"NCT00971932","Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and\u002For Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[40],33,[1229],[1141,1386,1231],"Cisplatin\u002FCarboplatin",{"trials":1388,"activeCount":8},[1389,1393],{"nctId":1224,"briefTitle":1225,"status":56,"phases":1390,"primaryCompletion":900,"completion":371,"start":76,"enrollment":1227,"conditions":1391,"interventions":1392},[41],[1229],[1141,1122,1231],{"nctId":1394,"briefTitle":1395,"status":56,"phases":1396,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT02383966","Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer",[41],"2018-01-19","2021-12-20","2015-07-31",243,[1402],"Carcinoma, Squamous Cell of Head and Neck",[1141,1386,1142],{"trials":1405,"activeCount":8},[],{"trials":1407,"activeCount":8},[],{"intervention":1409,"totalTrials":196,"cells":1410},"Saizen®",{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1445,"NA":1447},{"trials":1412,"activeCount":8},[],{"trials":1414,"activeCount":8},[],{"trials":1416,"activeCount":8},[],{"trials":1418,"activeCount":8},[1419,1427,1435],{"nctId":1420,"briefTitle":1421,"status":56,"phases":1422,"primaryCompletion":93,"completion":93,"start":1318,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT00933686","Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome",[41],113,[1425],"Fibromyalgia",[1409],{"nctId":1428,"briefTitle":1429,"status":56,"phases":1430,"primaryCompletion":1008,"completion":1008,"start":1431,"enrollment":1272,"conditions":1432,"interventions":1434},"NCT00249821","Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age",[41],"2005-02-28",[1433],"Small Gestational Age (SGA)",[1409,1409],{"nctId":1436,"briefTitle":1437,"status":56,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":372,"conditions":1442,"interventions":1444},"NCT01746862","A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)",[41],"2014-08","2015-03","2012-12",[1443],"Idiopathic Short Stature",[1409,1409],{"trials":1446,"activeCount":8},[],{"trials":1448,"activeCount":8},[],{"intervention":1450,"totalTrials":196,"cells":1451},"Recombinant human luteinizing hormone",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1476,"PHASE4":1488,"NA":1490},{"trials":1453,"activeCount":8},[],{"trials":1455,"activeCount":8},[],{"trials":1457,"activeCount":8},[1458,1468],{"nctId":1459,"briefTitle":1460,"status":56,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT01110707","A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve",[40],"2006-11-15","2005-01-10",131,[14,32],[1467,1450],"Recombinant human follicle stimulating hormone",{"nctId":1469,"briefTitle":1470,"status":130,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":155,"enrollment":313,"conditions":1473,"interventions":1474},"NCT01075815","A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age",[40],"2010-10",[14,32],[1450,1475],"Recombinant follicle-stimulating hormone",{"trials":1477,"activeCount":8},[1478],{"nctId":1479,"briefTitle":1480,"status":56,"phases":1481,"primaryCompletion":256,"completion":256,"start":221,"enrollment":1482,"conditions":1483,"interventions":1485},"NCT01084265","A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism",[41],31,[1484],"Hypogonadism",[1450,1486,1487],"Recombinant human follicle-stimulating hormone","Human chorionic gonadotropin",{"trials":1489,"activeCount":8},[],{"trials":1491,"activeCount":8},[],{"intervention":1493,"totalTrials":196,"cells":1494},"r-hFSH",{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1522,"PHASE4":1533,"NA":1535},{"trials":1496,"activeCount":8},[],{"trials":1498,"activeCount":8},[],{"trials":1500,"activeCount":8},[1501,1511],{"nctId":1502,"briefTitle":1503,"status":130,"phases":1504,"primaryCompletion":1472,"completion":1472,"start":1505,"enrollment":179,"conditions":1506,"interventions":1507},"NCT01079949","A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age",[40],"2007-11",[14,32],[1508,1493,1509,1510],"r-hLH + r-hFSH","Recombinant Human Choriogonadotropin","GnRH antagonist",{"nctId":1512,"briefTitle":1513,"status":56,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":1517,"conditions":1518,"interventions":1519},"NCT01735422","A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women",[40],"2001-07","1999-12",67,[14],[1493,1520,1521],"r-hLH","u-hCG",{"trials":1523,"activeCount":8},[1524],{"nctId":1525,"briefTitle":1526,"status":130,"phases":1527,"primaryCompletion":233,"completion":233,"start":1528,"enrollment":966,"conditions":1529,"interventions":1531},"NCT01071200","Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle",[41],"2005-03",[1530],"Reproductive Techniques, Assisted",[1532,1493],"Recombinant human Follicle Stimulating Hormone",{"trials":1534,"activeCount":8},[],{"trials":1536,"activeCount":8},[],{"intervention":1538,"totalTrials":287,"cells":1539},"Human Chorionic Gonadotropin",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1564,"NA":1566},{"trials":1541,"activeCount":8},[],{"trials":1543,"activeCount":8},[],{"trials":1545,"activeCount":8},[],{"trials":1547,"activeCount":8},[1548,1560],{"nctId":1549,"briefTitle":1550,"status":56,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":1159,"enrollment":1280,"conditions":1553,"interventions":1556},"NCT01863680","Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel",[41],"2014-10",[1554,1555],"Luteal Hormone Supplementation in In-vitro Fertilization","Embryo Transfer",[1557,1558,1559,1538],"COL-1620","Gonadotropin-releasing hormone (GnRH) analogue","Follicle-stimulating hormone",{"nctId":1479,"briefTitle":1480,"status":56,"phases":1561,"primaryCompletion":256,"completion":256,"start":221,"enrollment":1482,"conditions":1562,"interventions":1563},[41],[1484],[1450,1486,1487],{"trials":1565,"activeCount":8},[],{"trials":1567,"activeCount":8},[],{"intervention":1509,"totalTrials":287,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1580,"PHASE4":1591,"NA":1593},{"trials":1571,"activeCount":8},[],{"trials":1573,"activeCount":8},[],{"trials":1575,"activeCount":8},[1576],{"nctId":1502,"briefTitle":1503,"status":130,"phases":1577,"primaryCompletion":1472,"completion":1472,"start":1505,"enrollment":179,"conditions":1578,"interventions":1579},[40],[14,32],[1508,1493,1509,1510],{"trials":1581,"activeCount":8},[1582],{"nctId":1583,"briefTitle":1584,"status":56,"phases":1585,"primaryCompletion":75,"completion":103,"start":155,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT01185704","Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)",[41],136,[1588],"Polycystic Ovarian Syndrome",[1590,1590,1509,1467],"Cetrorelix acetate",{"trials":1592,"activeCount":8},[],{"trials":1594,"activeCount":8},[],{"intervention":1386,"totalTrials":287,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1607,"PHASE4":1613,"NA":1615},{"trials":1598,"activeCount":8},[],{"trials":1600,"activeCount":8},[],{"trials":1602,"activeCount":8},[1603],{"nctId":1380,"briefTitle":1381,"status":56,"phases":1604,"primaryCompletion":745,"start":220,"enrollment":1383,"conditions":1605,"interventions":1606},[40],[1229],[1141,1386,1231],{"trials":1608,"activeCount":8},[1609],{"nctId":1394,"briefTitle":1395,"status":56,"phases":1610,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":1611,"interventions":1612},[41],[1402],[1141,1386,1142],{"trials":1614,"activeCount":8},[],{"trials":1616,"activeCount":8},[],{"intervention":1618,"totalTrials":287,"cells":1619},"r-hCG",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1639,"PHASE4":1651,"NA":1653},{"trials":1621,"activeCount":8},[],{"trials":1623,"activeCount":8},[],{"trials":1625,"activeCount":8},[1626],{"nctId":1627,"briefTitle":1628,"status":56,"phases":1629,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":1633,"interventions":1635},"NCT01112358","Lutropin Alfa in Women at Risk of Poor Response",[40],"2007-01-30","2005-12-07",58,[1634],"Ovarian Stimulation",[1636,1520,1637,1618,1638],"r-FSH","Analogous GnRH antagonist","Progesterone",{"trials":1640,"activeCount":8},[1641],{"nctId":1642,"briefTitle":1643,"status":56,"phases":1644,"completion":1645,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1649},"NCT01081756","A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF\u002FET)",[41],"2004-09","2003-12",218,[14],[1618,1650],"Urinary-hCG",{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[],{"intervention":1638,"totalTrials":287,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1678,"NA":1680},{"trials":1658,"activeCount":8},[],{"trials":1660,"activeCount":8},[],{"trials":1662,"activeCount":8},[1663],{"nctId":1627,"briefTitle":1628,"status":56,"phases":1664,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":1665,"interventions":1666},[40],[1634],[1636,1520,1637,1618,1638],{"trials":1668,"activeCount":8},[1669],{"nctId":1670,"briefTitle":1671,"status":56,"phases":1672,"completion":1673,"start":168,"enrollment":1674,"conditions":1675,"interventions":1676},"NCT01081652","A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)",[41],"2005-05",238,[14],[1677,1638],"Micronised Progesterone",{"trials":1679,"activeCount":8},[],{"trials":1681,"activeCount":8},[],{"intervention":1683,"totalTrials":287,"cells":1684},"FOLFIRI",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1700,"PHASE4":1711,"NA":1713},{"trials":1686,"activeCount":8},[],{"trials":1688,"activeCount":8},[],{"trials":1690,"activeCount":8},[1691],{"nctId":1692,"briefTitle":1693,"status":56,"phases":1694,"primaryCompletion":112,"completion":112,"start":1160,"enrollment":1695,"conditions":1696,"interventions":1698},"NCT00778830","Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)",[39,40],289,[1697],"Metastatic Colorectal Cancer",[1141,1683,1699],"FOLFOX",{"trials":1701,"activeCount":8},[1702],{"nctId":1703,"briefTitle":1704,"status":56,"phases":1705,"primaryCompletion":1706,"completion":745,"start":168,"enrollment":1707,"conditions":1708,"interventions":1710},"NCT00154102","Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)",[41],"2006-12",1221,[1709],"Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer",[1141,1683],{"trials":1712,"activeCount":8},[],{"trials":1714,"activeCount":8},[],{"intervention":1210,"totalTrials":287,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1727,"PHASE4":1733,"NA":1735},{"trials":1718,"activeCount":8},[],{"trials":1720,"activeCount":8},[],{"trials":1722,"activeCount":8},[1723],{"nctId":1197,"briefTitle":1198,"status":56,"phases":1724,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1725,"interventions":1726},[40],[1205,1206],[1208,1209,1122,1210],{"trials":1728,"activeCount":8},[1729],{"nctId":1233,"briefTitle":1234,"status":56,"phases":1730,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":1731,"interventions":1732},[41],[1206],[1141,1210,1122],{"trials":1734,"activeCount":8},[],{"trials":1736,"activeCount":8},[],{"intervention":1738,"totalTrials":287,"cells":1739},"Oxaliplatin",{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1756,"PHASE4":1770,"NA":1772},{"trials":1741,"activeCount":8},[],{"trials":1743,"activeCount":8},[],{"trials":1745,"activeCount":8},[1746],{"nctId":1747,"briefTitle":1748,"status":56,"phases":1749,"primaryCompletion":234,"completion":104,"start":1750,"enrollment":1751,"conditions":1752,"interventions":1755},"NCT00125034","Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)",[40],"2005-07",344,[1753,1754],"Neoplasm Metastasis","Colorectal Cancer",[1141,1738],{"trials":1757,"activeCount":8},[1758],{"nctId":1759,"briefTitle":1760,"status":56,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1767},"NCT01228734","A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients",[41],"2016-01-25","2018-01-31","2010-09-09",553,[1697],[1141,1738,1768,1769],"Folinic Acid","5Fluorouracil",{"trials":1771,"activeCount":8},[],{"trials":1773,"activeCount":8},[],{"intervention":1775,"totalTrials":287,"cells":1776},"RNF",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1802,"NA":1804},{"trials":1778,"activeCount":8},[],{"trials":1780,"activeCount":8},[],{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[1785,1794],{"nctId":1786,"briefTitle":1787,"status":56,"phases":1788,"primaryCompletion":1057,"completion":1789,"start":1790,"enrollment":1791,"conditions":1792,"interventions":1793},"NCT00404352","REbif FLEXible Dosing in Early Multiple Sclerosis (MS)",[41],"2011-07","2006-11",517,[17],[1775,1775],{"nctId":1795,"briefTitle":1796,"status":56,"phases":1797,"primaryCompletion":1798,"completion":1799,"start":94,"enrollment":500,"conditions":1800,"interventions":1801},"NCT00813709","Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)",[41],"2011-08","2013-09",[17,159],[1775,1775,1775],{"trials":1803,"activeCount":8},[],{"trials":1805,"activeCount":8},[],{"intervention":1807,"totalTrials":519,"cells":1808},"MR Prednisone",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1828,"NA":1830},{"trials":1810,"activeCount":8},[],{"trials":1812,"activeCount":8},[],{"trials":1814,"activeCount":8},[],{"trials":1816,"activeCount":8},[1817],{"nctId":1818,"briefTitle":1819,"status":56,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1823,"conditions":1824,"interventions":1826},"NCT00146640","Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis",[41],"2007-01-31","2004-08-31",288,[1825],"Rheumatoid Arthritis",[1807,1827],"IR Prednisone",{"trials":1829,"activeCount":8},[],{"trials":1831,"activeCount":8},[],{"intervention":1827,"totalTrials":519,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":8},[],{"trials":1837,"activeCount":8},[],{"trials":1839,"activeCount":8},[],{"trials":1841,"activeCount":8},[1842],{"nctId":1818,"briefTitle":1819,"status":56,"phases":1843,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1823,"conditions":1844,"interventions":1845},[41],[1825],[1807,1827],{"trials":1847,"activeCount":8},[],{"trials":1849,"activeCount":8},[],{"intervention":1557,"totalTrials":519,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":8},[],{"trials":1855,"activeCount":8},[],{"trials":1857,"activeCount":8},[],{"trials":1859,"activeCount":8},[1860],{"nctId":1549,"briefTitle":1550,"status":56,"phases":1861,"primaryCompletion":1552,"completion":1552,"start":1159,"enrollment":1280,"conditions":1862,"interventions":1863},[41],[1554,1555],[1557,1558,1559,1538],{"trials":1865,"activeCount":8},[],{"trials":1867,"activeCount":8},[],{"intervention":1558,"totalTrials":519,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":8},[],{"trials":1873,"activeCount":8},[],{"trials":1875,"activeCount":8},[],{"trials":1877,"activeCount":8},[1878],{"nctId":1549,"briefTitle":1550,"status":56,"phases":1879,"primaryCompletion":1552,"completion":1552,"start":1159,"enrollment":1280,"conditions":1880,"interventions":1881},[41],[1554,1555],[1557,1558,1559,1538],{"trials":1883,"activeCount":8},[],{"trials":1885,"activeCount":8},[],{"intervention":1559,"totalTrials":519,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1900,"NA":1902},{"trials":1889,"activeCount":8},[],{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[1896],{"nctId":1549,"briefTitle":1550,"status":56,"phases":1897,"primaryCompletion":1552,"completion":1552,"start":1159,"enrollment":1280,"conditions":1898,"interventions":1899},[41],[1554,1555],[1557,1558,1559,1538],{"trials":1901,"activeCount":8},[],{"trials":1903,"activeCount":8},[],{"intervention":1905,"totalTrials":519,"cells":1906},"Bisoprolol\u002FAmlodipine",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1922,"NA":1924},{"trials":1908,"activeCount":8},[],{"trials":1910,"activeCount":8},[],{"trials":1912,"activeCount":8},[],{"trials":1914,"activeCount":8},[1915],{"nctId":1916,"briefTitle":1917,"status":56,"phases":1918,"primaryCompletion":1440,"completion":1440,"start":1919,"enrollment":189,"conditions":1920,"interventions":1921},"NCT01977794","Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension",[41],"2014-03",[29],[1905,1905],{"trials":1923,"activeCount":8},[],{"trials":1925,"activeCount":8},[],{"intervention":1927,"totalTrials":519,"cells":1928},"L-PZQ ODT 50 mg\u002Fkg",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1948,"NA":1950},{"trials":1930,"activeCount":8},[],{"trials":1932,"activeCount":8},[],{"trials":1934,"activeCount":8},[],{"trials":1936,"activeCount":8},[1937],{"nctId":1938,"briefTitle":1939,"status":56,"phases":1940,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1823,"conditions":1943,"interventions":1945},"NCT03845140","L-PZQ ODT in Schistosoma Infected Children",[41],"2021-10-11","2019-09-02",[1944],"Schistosomiasis",[1927,1946,1947],"Biltricide®","L-PZQ ODT 60 mg\u002Fkg",{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"intervention":1946,"totalTrials":519,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1966,"NA":1968},{"trials":1955,"activeCount":8},[],{"trials":1957,"activeCount":8},[],{"trials":1959,"activeCount":8},[],{"trials":1961,"activeCount":8},[1962],{"nctId":1938,"briefTitle":1939,"status":56,"phases":1963,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1823,"conditions":1964,"interventions":1965},[41],[1944],[1927,1946,1947],{"trials":1967,"activeCount":8},[],{"trials":1969,"activeCount":8},[],{"intervention":1947,"totalTrials":519,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1984,"NA":1986},{"trials":1973,"activeCount":8},[],{"trials":1975,"activeCount":8},[],{"trials":1977,"activeCount":8},[],{"trials":1979,"activeCount":8},[1980],{"nctId":1938,"briefTitle":1939,"status":56,"phases":1981,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1823,"conditions":1982,"interventions":1983},[41],[1944],[1927,1946,1947],{"trials":1985,"activeCount":8},[],{"trials":1987,"activeCount":8},[],{"intervention":1362,"totalTrials":519,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":2002,"NA":2004},{"trials":1991,"activeCount":8},[],{"trials":1993,"activeCount":8},[],{"trials":1995,"activeCount":8},[],{"trials":1997,"activeCount":8},[1998],{"nctId":1353,"briefTitle":1354,"status":130,"phases":1999,"primaryCompletion":1356,"completion":1356,"start":382,"enrollment":1357,"conditions":2000,"interventions":2001},[41],[14,1359,1360],[410,1362,1306],{"trials":2003,"activeCount":8},[],{"trials":2005,"activeCount":8},[],{"intervention":2007,"totalTrials":519,"cells":2008},"Rebif New Formulation + prophylactic Ibuprofen",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2027,"NA":2029},{"trials":2010,"activeCount":8},[],{"trials":2012,"activeCount":8},[],{"trials":2014,"activeCount":8},[],{"trials":2016,"activeCount":8},[2017],{"nctId":2018,"briefTitle":2019,"status":56,"phases":2020,"primaryCompletion":312,"completion":312,"start":2021,"enrollment":2022,"conditions":2023,"interventions":2025},"NCT00619307","Transition to Rebif New Formulation",[41],"2007-07",117,[2024],"Relapsing Multiple Sclerosis",[2007,2026],"Rebif New Formulation + ibuprofen PRN",{"trials":2028,"activeCount":8},[],{"trials":2030,"activeCount":8},[],{"intervention":2026,"totalTrials":519,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2045,"NA":2047},{"trials":2034,"activeCount":8},[],{"trials":2036,"activeCount":8},[],{"trials":2038,"activeCount":8},[],{"trials":2040,"activeCount":8},[2041],{"nctId":2018,"briefTitle":2019,"status":56,"phases":2042,"primaryCompletion":312,"completion":312,"start":2021,"enrollment":2022,"conditions":2043,"interventions":2044},[41],[2024],[2007,2026],{"trials":2046,"activeCount":8},[],{"trials":2048,"activeCount":8},[],{"intervention":2050,"totalTrials":519,"cells":2051},"Raptiva",{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2069,"NA":2071},{"trials":2053,"activeCount":8},[],{"trials":2055,"activeCount":8},[],{"trials":2057,"activeCount":8},[],{"trials":2059,"activeCount":8},[2060],{"nctId":2061,"briefTitle":2062,"status":56,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2068},"NCT00256139","CLEAR Study: Clinical Experience Acquired With Raptiva Study",[41],"2004-10","2003-03",793,[259],[2050],{"trials":2070,"activeCount":8},[],{"trials":2072,"activeCount":8},[],{"intervention":2074,"totalTrials":519,"cells":2075},"MSJ-0011",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2082,"PHASE4":2098,"NA":2100},{"trials":2077,"activeCount":8},[],{"trials":2079,"activeCount":8},[],{"trials":2081,"activeCount":8},[],{"trials":2083,"activeCount":8},[2084],{"nctId":2085,"briefTitle":2086,"status":56,"phases":2087,"primaryCompletion":2088,"completion":813,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2095},"NCT01653743","Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women",[41],"2014-11","2012-09",81,[2092,2093,2094,1588],"Anovulation","Oligo-ovulation","Hypothalamic-pituitary Dysfunction",[2074,2096,2097],"urinary hCG","Follitropin alpha",{"trials":2099,"activeCount":8},[],{"trials":2101,"activeCount":8},[],{"intervention":2096,"totalTrials":519,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2116,"NA":2118},{"trials":2105,"activeCount":8},[],{"trials":2107,"activeCount":8},[],{"trials":2109,"activeCount":8},[],{"trials":2111,"activeCount":8},[2112],{"nctId":2085,"briefTitle":2086,"status":56,"phases":2113,"primaryCompletion":2088,"completion":813,"start":2089,"enrollment":2090,"conditions":2114,"interventions":2115},[41],[2092,2093,2094,1588],[2074,2096,2097],{"trials":2117,"activeCount":8},[],{"trials":2119,"activeCount":8},[],{"intervention":2121,"totalTrials":519,"cells":2122},"Gonalef®",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2140,"NA":2142},{"trials":2124,"activeCount":8},[],{"trials":2126,"activeCount":8},[],{"trials":2128,"activeCount":8},[],{"trials":2130,"activeCount":8},[2131],{"nctId":2132,"briefTitle":2133,"status":56,"phases":2134,"primaryCompletion":1318,"completion":1318,"start":2135,"enrollment":2136,"conditions":2137,"interventions":2138},"NCT01185782","SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women",[41],"2007-02",300,[14,32],[2121,2139],"Purified pituitary gonadotropin",{"trials":2141,"activeCount":8},[],{"trials":2143,"activeCount":8},[],{"intervention":2139,"totalTrials":519,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2158,"NA":2160},{"trials":2147,"activeCount":8},[],{"trials":2149,"activeCount":8},[],{"trials":2151,"activeCount":8},[],{"trials":2153,"activeCount":8},[2154],{"nctId":2132,"briefTitle":2133,"status":56,"phases":2155,"primaryCompletion":1318,"completion":1318,"start":2135,"enrollment":2136,"conditions":2156,"interventions":2157},[41],[14,32],[2121,2139],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[],{"intervention":2163,"totalTrials":519,"cells":2164},"Cetuximab + Platinum",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2171,"PHASE4":2182,"NA":2184},{"trials":2166,"activeCount":8},[],{"trials":2168,"activeCount":8},[],{"trials":2170,"activeCount":8},[],{"trials":2172,"activeCount":8},[2173],{"nctId":2174,"briefTitle":2175,"status":56,"phases":2176,"primaryCompletion":234,"completion":900,"start":602,"enrollment":2177,"conditions":2178,"interventions":2180},"NCT00122460","Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and\u002For Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)",[41],442,[2179],"Head and Neck Cancer",[2163,2181],"Platinum (Cisplatin or Carboplatin) + 5-FU",{"trials":2183,"activeCount":8},[],{"trials":2185,"activeCount":8},[],{"intervention":2181,"totalTrials":519,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":8},[],{"trials":2191,"activeCount":8},[],{"trials":2193,"activeCount":8},[],{"trials":2195,"activeCount":8},[2196],{"nctId":2174,"briefTitle":2175,"status":56,"phases":2197,"primaryCompletion":234,"completion":900,"start":602,"enrollment":2177,"conditions":2198,"interventions":2199},[41],[2179],[2163,2181],{"trials":2201,"activeCount":8},[],{"trials":2203,"activeCount":8},[],{"intervention":2205,"totalTrials":519,"cells":2206},"Cetuximab plus Platinum-based Doublet Chemotherapy",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2226,"NA":2228},{"trials":2208,"activeCount":8},[],{"trials":2210,"activeCount":8},[],{"trials":2212,"activeCount":8},[],{"trials":2214,"activeCount":8},[2215],{"nctId":2216,"briefTitle":2217,"status":56,"phases":2218,"primaryCompletion":85,"completion":721,"start":2219,"enrollment":2220,"conditions":2221,"interventions":2223},"NCT00820755","Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)",[41],"2009-01",583,[2222],"Non-Small Cell Lung Cancer (NSCLC)",[2205,2224,2225],"Cetuximab 500 mg\u002Fm^2","Cetuximab 250 mg\u002Fm^2",{"trials":2227,"activeCount":8},[],{"trials":2229,"activeCount":8},[],{"intervention":2224,"totalTrials":519,"cells":2231},{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2238,"PHASE4":2244,"NA":2246},{"trials":2233,"activeCount":8},[],{"trials":2235,"activeCount":8},[],{"trials":2237,"activeCount":8},[],{"trials":2239,"activeCount":8},[2240],{"nctId":2216,"briefTitle":2217,"status":56,"phases":2241,"primaryCompletion":85,"completion":721,"start":2219,"enrollment":2220,"conditions":2242,"interventions":2243},[41],[2222],[2205,2224,2225],{"trials":2245,"activeCount":8},[],{"trials":2247,"activeCount":8},[],{"intervention":2225,"totalTrials":519,"cells":2249},{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2262,"NA":2264},{"trials":2251,"activeCount":8},[],{"trials":2253,"activeCount":8},[],{"trials":2255,"activeCount":8},[],{"trials":2257,"activeCount":8},[2258],{"nctId":2216,"briefTitle":2217,"status":56,"phases":2259,"primaryCompletion":85,"completion":721,"start":2219,"enrollment":2220,"conditions":2260,"interventions":2261},[41],[2222],[2205,2224,2225],{"trials":2263,"activeCount":8},[],{"trials":2265,"activeCount":8},[],{"intervention":1590,"totalTrials":519,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2280,"NA":2282},{"trials":2269,"activeCount":8},[],{"trials":2271,"activeCount":8},[],{"trials":2273,"activeCount":8},[],{"trials":2275,"activeCount":8},[2276],{"nctId":1583,"briefTitle":1584,"status":56,"phases":2277,"primaryCompletion":75,"completion":103,"start":155,"enrollment":1586,"conditions":2278,"interventions":2279},[41],[1588],[1590,1590,1509,1467],{"trials":2281,"activeCount":8},[],{"trials":2283,"activeCount":8},[],{"intervention":2285,"totalTrials":519,"cells":2286},"Saizen® A",{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2293,"PHASE4":2306,"NA":2308},{"trials":2288,"activeCount":8},[],{"trials":2290,"activeCount":8},[],{"trials":2292,"activeCount":8},[],{"trials":2294,"activeCount":8},[2295],{"nctId":2296,"briefTitle":2297,"status":56,"phases":2298,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2301,"conditions":2302,"interventions":2304},"NCT01400698","Saizen in Intra-uterine Growth Retardation",[41],"2010-02","1998-11",91,[2303],"Children Born With Serious Intra-uterine Growth Retardation",[2285,2305],"Saizen® B",{"trials":2307,"activeCount":8},[],{"trials":2309,"activeCount":8},[],{"intervention":2305,"totalTrials":519,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2324,"NA":2326},{"trials":2313,"activeCount":8},[],{"trials":2315,"activeCount":8},[],{"trials":2317,"activeCount":8},[],{"trials":2319,"activeCount":8},[2320],{"nctId":2296,"briefTitle":2297,"status":56,"phases":2321,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2301,"conditions":2322,"interventions":2323},[41],[2303],[2285,2305],{"trials":2325,"activeCount":8},[],{"trials":2327,"activeCount":8},[],{"intervention":2329,"totalTrials":519,"cells":2330},"Follitropin alfa liquid formulation",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2347,"NA":2349},{"trials":2332,"activeCount":8},[],{"trials":2334,"activeCount":8},[],{"trials":2336,"activeCount":8},[],{"trials":2338,"activeCount":8},[2339],{"nctId":2340,"briefTitle":2341,"status":56,"phases":2342,"primaryCompletion":1645,"completion":1645,"start":2343,"enrollment":337,"conditions":2344,"interventions":2345},"NCT01081639","To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen",[41],"2003-11",[14,32],[2329,2346],"Follitropin beta liquid formulation",{"trials":2348,"activeCount":8},[],{"trials":2350,"activeCount":8},[],{"intervention":2346,"totalTrials":519,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2365,"NA":2367},{"trials":2354,"activeCount":8},[],{"trials":2356,"activeCount":8},[],{"trials":2358,"activeCount":8},[],{"trials":2360,"activeCount":8},[2361],{"nctId":2340,"briefTitle":2341,"status":56,"phases":2362,"primaryCompletion":1645,"completion":1645,"start":2343,"enrollment":337,"conditions":2363,"interventions":2364},[41],[14,32],[2329,2346],{"trials":2366,"activeCount":8},[],{"trials":2368,"activeCount":8},[],{"intervention":2370,"totalTrials":519,"cells":2371},"Cetuximab + concomitant boost radiotherapy",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2387,"NA":2389},{"trials":2373,"activeCount":8},[],{"trials":2375,"activeCount":8},[],{"trials":2377,"activeCount":8},[],{"trials":2379,"activeCount":8},[2380],{"nctId":2381,"briefTitle":2382,"status":56,"phases":2383,"primaryCompletion":2384,"completion":498,"start":1160,"enrollment":304,"conditions":2385,"interventions":2386},"NCT01012258","Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects",[41],"2010-09",[1229],[2370],{"trials":2388,"activeCount":8},[],{"trials":2390,"activeCount":8},[],{"intervention":2392,"totalTrials":519,"cells":2393},"cetuximab + cisplatin + vinorelbine",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2411,"NA":2413},{"trials":2395,"activeCount":8},[],{"trials":2397,"activeCount":8},[],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[2402],{"nctId":2403,"briefTitle":2404,"status":56,"phases":2405,"primaryCompletion":2021,"completion":382,"start":2064,"enrollment":2406,"conditions":2407,"interventions":2409},"NCT00148798","Study of Cisplatin\u002FVinorelbine +\u002F- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)",[41],1861,[2408],"Non Small Cell Lung Cancer (NSCLC)",[2392,2410],"cisplatin + vinorelbine",{"trials":2412,"activeCount":8},[],{"trials":2414,"activeCount":8},[],{"intervention":2410,"totalTrials":519,"cells":2416},{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2429,"NA":2431},{"trials":2418,"activeCount":8},[],{"trials":2420,"activeCount":8},[],{"trials":2422,"activeCount":8},[],{"trials":2424,"activeCount":8},[2425],{"nctId":2403,"briefTitle":2404,"status":56,"phases":2426,"primaryCompletion":2021,"completion":382,"start":2064,"enrollment":2406,"conditions":2427,"interventions":2428},[41],[2408],[2392,2410],{"trials":2430,"activeCount":8},[],{"trials":2432,"activeCount":8},[],{"intervention":1677,"totalTrials":519,"cells":2434},{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2447,"NA":2449},{"trials":2436,"activeCount":8},[],{"trials":2438,"activeCount":8},[],{"trials":2440,"activeCount":8},[],{"trials":2442,"activeCount":8},[2443],{"nctId":1670,"briefTitle":1671,"status":56,"phases":2444,"completion":1673,"start":168,"enrollment":1674,"conditions":2445,"interventions":2446},[41],[14],[1677,1638],{"trials":2448,"activeCount":8},[],{"trials":2450,"activeCount":8},[],{"intervention":2452,"totalTrials":519,"cells":2453},"F0434",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2473,"NA":2475},{"trials":2455,"activeCount":8},[],{"trials":2457,"activeCount":8},[],{"trials":2459,"activeCount":8},[],{"trials":2461,"activeCount":8},[2462],{"nctId":2463,"briefTitle":2464,"status":56,"phases":2465,"primaryCompletion":2299,"completion":2299,"start":2466,"enrollment":2467,"conditions":2468,"interventions":2471},"NCT01263132","Neuropathic Pain Management",[41],"2008-02",104,[2469,2470],"Diabetic Neuropathies","Polyneuropathies",[2452,2472],"Gabapentin",{"trials":2474,"activeCount":8},[],{"trials":2476,"activeCount":8},[],{"intervention":2472,"totalTrials":519,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2485,"PHASE4":2491,"NA":2493},{"trials":2480,"activeCount":8},[],{"trials":2482,"activeCount":8},[],{"trials":2484,"activeCount":8},[],{"trials":2486,"activeCount":8},[2487],{"nctId":2463,"briefTitle":2464,"status":56,"phases":2488,"primaryCompletion":2299,"completion":2299,"start":2466,"enrollment":2467,"conditions":2489,"interventions":2490},[41],[2469,2470],[2452,2472],{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[],{"intervention":1486,"totalTrials":519,"cells":2496},{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2509,"NA":2511},{"trials":2498,"activeCount":8},[],{"trials":2500,"activeCount":8},[],{"trials":2502,"activeCount":8},[],{"trials":2504,"activeCount":8},[2505],{"nctId":1479,"briefTitle":1480,"status":56,"phases":2506,"primaryCompletion":256,"completion":256,"start":221,"enrollment":1482,"conditions":2507,"interventions":2508},[41],[1484],[1450,1486,1487],{"trials":2510,"activeCount":8},[],{"trials":2512,"activeCount":8},[],{"intervention":1768,"totalTrials":519,"cells":2514},{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2521,"PHASE4":2527,"NA":2529},{"trials":2516,"activeCount":8},[],{"trials":2518,"activeCount":8},[],{"trials":2520,"activeCount":8},[],{"trials":2522,"activeCount":8},[2523],{"nctId":1759,"briefTitle":1760,"status":56,"phases":2524,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":2525,"interventions":2526},[41],[1697],[1141,1738,1768,1769],{"trials":2528,"activeCount":8},[],{"trials":2530,"activeCount":8},[],{"intervention":1769,"totalTrials":519,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2545,"NA":2547},{"trials":2534,"activeCount":8},[],{"trials":2536,"activeCount":8},[],{"trials":2538,"activeCount":8},[],{"trials":2540,"activeCount":8},[2541],{"nctId":1759,"briefTitle":1760,"status":56,"phases":2542,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":2543,"interventions":2544},[41],[1697],[1141,1738,1768,1769],{"trials":2546,"activeCount":8},[],{"trials":2548,"activeCount":8},[],{"intervention":1650,"totalTrials":519,"cells":2550},{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2555,"PHASE3":2557,"PHASE4":2563,"NA":2565},{"trials":2552,"activeCount":8},[],{"trials":2554,"activeCount":8},[],{"trials":2556,"activeCount":8},[],{"trials":2558,"activeCount":8},[2559],{"nctId":1642,"briefTitle":1643,"status":56,"phases":2560,"completion":1645,"start":1646,"enrollment":1647,"conditions":2561,"interventions":2562},[41],[14],[1618,1650],{"trials":2564,"activeCount":8},[],{"trials":2566,"activeCount":8},[],{"intervention":1193,"totalTrials":279,"cells":2568},{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2601,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2570,"activeCount":8},[],{"trials":2572,"activeCount":8},[2573,2582,2592],{"nctId":2574,"briefTitle":2575,"status":56,"phases":2576,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":24,"conditions":2579,"interventions":2580},"NCT03492437","Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate",[39],"2018-08-27","2018-05-17",[20],[2581,1193],"Dabigatran Etexilate",{"nctId":2583,"briefTitle":2584,"status":56,"phases":2585,"primaryCompletion":2586,"completion":2586,"start":2587,"enrollment":2588,"conditions":2589,"interventions":2590},"NCT03531762","Effect of a Proton Pump Inhibitor on the PK of Tepotinib",[39],"2018-07-02","2018-05-14",12,[20],[1193,2591],"Omeprazole",{"nctId":2593,"briefTitle":2594,"status":56,"phases":2595,"primaryCompletion":2596,"completion":1175,"start":2597,"enrollment":2588,"conditions":2598,"interventions":2599},"NCT03628339","Effect of Tepotinib on PK of CYP3A Substrate Midazolam",[39],"2018-10-25","2018-08-20",[20],[2600,1193],"Midazolam",{"trials":2602,"activeCount":8},[2603,2613,2617],{"nctId":2604,"briefTitle":2605,"status":56,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":2608,"enrollment":2609,"conditions":2610,"interventions":2612},"NCT02115373","c-Met Second-Line Hepatocellular Carcinoma",[39,40],"2018-02-14","2014-05-18",66,[2611],"Carcinoma, Hepatocellular",[1193,1193],{"nctId":1183,"briefTitle":1184,"status":56,"phases":2614,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":2615,"interventions":2616},[39,40],[1191],[1193,1194,1195,1122,1181],{"nctId":2618,"briefTitle":2619,"status":56,"phases":2620,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":2022,"conditions":2624,"interventions":2625},"NCT01988493","Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma",[39,40],"2018-02-05","2020-12-03","2014-01-06",[2611],[2626,2627,2628,1193,2629],"Tepotinib 300 mg","Tepotinib 500 mg","Tepotinib 1000 mg","Sorafenib",{"trials":2631,"activeCount":8},[],{"trials":2633,"activeCount":8},[],{"trials":2635,"activeCount":8},[],{"intervention":1166,"totalTrials":196,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2652,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2639,"activeCount":8},[],{"trials":2641,"activeCount":8},[2642],{"nctId":2643,"briefTitle":2644,"status":56,"phases":2645,"primaryCompletion":404,"completion":1762,"start":2646,"enrollment":24,"conditions":2647,"interventions":2650},"NCT01833546","A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer",[39],"2013-04-18",[2648,2649],"Solid Tumor","Pancreatic Cancer",[2651,1166],"Evofosfamide",{"trials":2653,"activeCount":8},[2654,2658],{"nctId":1156,"briefTitle":1157,"status":56,"phases":2655,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":2656,"interventions":2657},[40],[1163],[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],{"nctId":1170,"briefTitle":1171,"status":56,"phases":2659,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":2660,"interventions":2661},[40],[1178],[1180,1141,1166,1122,1181],{"trials":2663,"activeCount":8},[],{"trials":2665,"activeCount":8},[],{"trials":2667,"activeCount":8},[],{"intervention":2669,"totalTrials":287,"cells":2670},"Emfilermin, recombinant human leukemia inhibitory factor",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2696,"PHASE4":2698,"NA":2700},{"trials":2672,"activeCount":8},[],{"trials":2674,"activeCount":8},[],{"trials":2676,"activeCount":8},[2677,2687],{"nctId":2678,"briefTitle":2679,"status":56,"phases":2680,"completion":2681,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2686},"NCT00504530","r-hLIF for Improving Embryo Implantation in IVF",[39,40],"2002-04","2001-09",50,[2685],"Infertility Implantation Failure",[2669],{"nctId":2688,"briefTitle":2689,"status":56,"phases":2690,"primaryCompletion":2691,"completion":2691,"start":2692,"enrollment":2693,"conditions":2694,"interventions":2695},"NCT00504608","A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure",[39,40],"2004-04","2003-04",150,[2685],[2669],{"trials":2697,"activeCount":8},[],{"trials":2699,"activeCount":8},[],{"trials":2701,"activeCount":8},[],{"intervention":1181,"totalTrials":287,"cells":2703},{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2705,"activeCount":8},[],{"trials":2707,"activeCount":8},[],{"trials":2709,"activeCount":8},[2710,2714],{"nctId":1170,"briefTitle":1171,"status":56,"phases":2711,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":2712,"interventions":2713},[40],[1178],[1180,1141,1166,1122,1181],{"nctId":1183,"briefTitle":1184,"status":56,"phases":2715,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":2716,"interventions":2717},[39,40],[1191],[1193,1194,1195,1122,1181],{"trials":2719,"activeCount":8},[],{"trials":2721,"activeCount":8},[],{"trials":2723,"activeCount":8},[],{"intervention":1520,"totalTrials":287,"cells":2725},{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[],{"trials":2731,"activeCount":8},[2732,2736],{"nctId":1627,"briefTitle":1628,"status":56,"phases":2733,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":2734,"interventions":2735},[40],[1634],[1636,1520,1637,1618,1638],{"nctId":1512,"briefTitle":1513,"status":56,"phases":2737,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":1517,"conditions":2738,"interventions":2739},[40],[14],[1493,1520,1521],{"trials":2741,"activeCount":8},[],{"trials":2743,"activeCount":8},[],{"trials":2745,"activeCount":8},[],{"intervention":2747,"totalTrials":287,"cells":2748},"Cyclophosphamide",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2761,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2750,"activeCount":8},[],{"trials":2752,"activeCount":8},[2753],{"nctId":2754,"briefTitle":2755,"status":768,"phases":2756,"start":2757,"enrollment":8,"conditions":2758,"interventions":2760},"NCT01731587","Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer",[39],"2001-01",[2759],"Non-small Cell Lung Cancer (NSCLC) Stage III",[2747],{"trials":2762,"activeCount":8},[2763],{"nctId":2764,"briefTitle":2765,"status":56,"phases":2766,"primaryCompletion":2767,"completion":2767,"start":103,"enrollment":2768,"conditions":2769,"interventions":2771},"NCT01507103","Tecemotide (L-BLP25) in Rectal Cancer",[40],"2014-06",124,[2770],"Rectal Cancer",[1265,2772],"cyclophosphamide",{"trials":2774,"activeCount":8},[],{"trials":2776,"activeCount":8},[],{"trials":2778,"activeCount":8},[],{"intervention":2780,"totalTrials":519,"cells":2781},"Rituximab",{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2786,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2783,"activeCount":8},[],{"trials":2785,"activeCount":8},[],{"trials":2787,"activeCount":8},[2788],{"nctId":2789,"briefTitle":2790,"status":56,"phases":2791,"primaryCompletion":1472,"completion":1472,"start":2792,"enrollment":1058,"conditions":2793,"interventions":2794},"NCT00664521","Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)",[40],"2008-03",[1825],[2780,2795],"Atacicept",{"trials":2797,"activeCount":8},[],{"trials":2799,"activeCount":8},[],{"trials":2801,"activeCount":8},[],{"intervention":2795,"totalTrials":519,"cells":2803},{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2814,"PHASE4":2816,"NA":2818},{"trials":2805,"activeCount":8},[],{"trials":2807,"activeCount":8},[],{"trials":2809,"activeCount":8},[2810],{"nctId":2789,"briefTitle":2790,"status":56,"phases":2811,"primaryCompletion":1472,"completion":1472,"start":2792,"enrollment":1058,"conditions":2812,"interventions":2813},[40],[1825],[2780,2795],{"trials":2815,"activeCount":8},[],{"trials":2817,"activeCount":8},[],{"trials":2819,"activeCount":8},[],{"intervention":1139,"totalTrials":519,"cells":2821},{"EARLY_PHASE1":2822,"PHASE1":2824,"PHASE2":2826,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2823,"activeCount":8},[],{"trials":2825,"activeCount":8},[],{"trials":2827,"activeCount":8},[2828],{"nctId":1131,"briefTitle":1132,"status":56,"phases":2829,"primaryCompletion":499,"completion":721,"start":1134,"enrollment":1135,"conditions":2830,"interventions":2831},[39,40],[1137],[1139,1140,1141,1142,1122],{"trials":2833,"activeCount":8},[],{"trials":2835,"activeCount":8},[],{"trials":2837,"activeCount":8},[],{"intervention":1140,"totalTrials":519,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2841,"activeCount":8},[],{"trials":2843,"activeCount":8},[],{"trials":2845,"activeCount":8},[2846],{"nctId":1131,"briefTitle":1132,"status":56,"phases":2847,"primaryCompletion":499,"completion":721,"start":1134,"enrollment":1135,"conditions":2848,"interventions":2849},[39,40],[1137],[1139,1140,1141,1142,1122],{"trials":2851,"activeCount":8},[],{"trials":2853,"activeCount":8},[],{"trials":2855,"activeCount":8},[],{"intervention":1153,"totalTrials":519,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2859,"activeCount":8},[],{"trials":2861,"activeCount":8},[],{"trials":2863,"activeCount":8},[2864],{"nctId":1144,"briefTitle":1145,"status":56,"phases":2865,"primaryCompletion":220,"completion":1147,"start":1148,"enrollment":1149,"conditions":2866,"interventions":2867},[40],[1151],[1153,1154],{"trials":2869,"activeCount":8},[],{"trials":2871,"activeCount":8},[],{"trials":2873,"activeCount":8},[],{"intervention":1165,"totalTrials":519,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2877,"activeCount":8},[],{"trials":2879,"activeCount":8},[],{"trials":2881,"activeCount":8},[2882],{"nctId":1156,"briefTitle":1157,"status":56,"phases":2883,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":2884,"interventions":2885},[40],[1163],[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],{"trials":2887,"activeCount":8},[],{"trials":2889,"activeCount":8},[],{"trials":2891,"activeCount":8},[],{"intervention":1167,"totalTrials":519,"cells":2893},{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2895,"activeCount":8},[],{"trials":2897,"activeCount":8},[],{"trials":2899,"activeCount":8},[2900],{"nctId":1156,"briefTitle":1157,"status":56,"phases":2901,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":2902,"interventions":2903},[40],[1163],[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],{"trials":2905,"activeCount":8},[],{"trials":2907,"activeCount":8},[],{"trials":2909,"activeCount":8},[],{"intervention":1168,"totalTrials":519,"cells":2911},{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2913,"activeCount":8},[],{"trials":2915,"activeCount":8},[],{"trials":2917,"activeCount":8},[2918],{"nctId":1156,"briefTitle":1157,"status":56,"phases":2919,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":2920,"interventions":2921},[40],[1163],[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],{"trials":2923,"activeCount":8},[],{"trials":2925,"activeCount":8},[],{"trials":2927,"activeCount":8},[],{"intervention":2929,"totalTrials":519,"cells":2930},"Minocycline",{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2932,"activeCount":8},[],{"trials":2934,"activeCount":8},[],{"trials":2936,"activeCount":8},[2937],{"nctId":2938,"briefTitle":2939,"status":130,"phases":2940,"primaryCompletion":536,"completion":536,"start":2941,"enrollment":2942,"conditions":2943,"interventions":2944},"NCT01134627","Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]",[40],"2006-02",305,[26],[2929],{"trials":2946,"activeCount":8},[],{"trials":2948,"activeCount":8},[],{"trials":2950,"activeCount":8},[],{"intervention":2952,"totalTrials":519,"cells":2953},"UFOX + Cetuximab",{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2955,"activeCount":8},[],{"trials":2957,"activeCount":8},[],{"trials":2959,"activeCount":8},[2960],{"nctId":2961,"briefTitle":2962,"status":56,"phases":2963,"primaryCompletion":311,"completion":382,"start":2135,"enrollment":2964,"conditions":2965,"interventions":2967},"NCT00439517","Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.",[40],302,[2966],"Previously Untreated Metastatic Colorectal Cancer",[2952,2968],"FOLFOX4 + Cetuximab",{"trials":2970,"activeCount":8},[],{"trials":2972,"activeCount":8},[],{"trials":2974,"activeCount":8},[],{"intervention":2968,"totalTrials":519,"cells":2976},{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2981,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2978,"activeCount":8},[],{"trials":2980,"activeCount":8},[],{"trials":2982,"activeCount":8},[2983],{"nctId":2961,"briefTitle":2962,"status":56,"phases":2984,"primaryCompletion":311,"completion":382,"start":2135,"enrollment":2964,"conditions":2985,"interventions":2986},[40],[2966],[2952,2968],{"trials":2988,"activeCount":8},[],{"trials":2990,"activeCount":8},[],{"trials":2992,"activeCount":8},[],{"intervention":2994,"totalTrials":519,"cells":2995},"TH-302",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":2997,"activeCount":8},[],{"trials":2999,"activeCount":8},[],{"trials":3001,"activeCount":8},[3002],{"nctId":3003,"briefTitle":3004,"status":130,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":279,"conditions":3008,"interventions":3010},"NCT02255110","A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma",[40],"2016-01-12","2014-12-10",[3009],"Soft Tissue Sarcoma",[2994,3011],"Doxorubicin",{"trials":3013,"activeCount":8},[],{"trials":3015,"activeCount":8},[],{"trials":3017,"activeCount":8},[],{"intervention":3011,"totalTrials":519,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":8},[],{"trials":3023,"activeCount":8},[],{"trials":3025,"activeCount":8},[3026],{"nctId":3003,"briefTitle":3004,"status":130,"phases":3027,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":279,"conditions":3028,"interventions":3029},[40],[3009],[2994,3011],{"trials":3031,"activeCount":8},[],{"trials":3033,"activeCount":8},[],{"trials":3035,"activeCount":8},[],{"intervention":1508,"totalTrials":519,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":8},[],{"trials":3041,"activeCount":8},[],{"trials":3043,"activeCount":8},[3044],{"nctId":1502,"briefTitle":1503,"status":130,"phases":3045,"primaryCompletion":1472,"completion":1472,"start":1505,"enrollment":179,"conditions":3046,"interventions":3047},[40],[14,32],[1508,1493,1509,1510],{"trials":3049,"activeCount":8},[],{"trials":3051,"activeCount":8},[],{"trials":3053,"activeCount":8},[],{"intervention":1322,"totalTrials":519,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3057,"activeCount":8},[],{"trials":3059,"activeCount":8},[],{"trials":3061,"activeCount":8},[3062],{"nctId":1315,"briefTitle":1316,"status":130,"phases":3063,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":3064,"interventions":3065},[40],[32],[1322,1323,1324,1325,1326,1306],{"trials":3067,"activeCount":8},[],{"trials":3069,"activeCount":8},[],{"trials":3071,"activeCount":8},[],{"intervention":1323,"totalTrials":519,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":8},[],{"trials":3077,"activeCount":8},[],{"trials":3079,"activeCount":8},[3080],{"nctId":1315,"briefTitle":1316,"status":130,"phases":3081,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":3082,"interventions":3083},[40],[32],[1322,1323,1324,1325,1326,1306],{"trials":3085,"activeCount":8},[],{"trials":3087,"activeCount":8},[],{"trials":3089,"activeCount":8},[],{"intervention":1324,"totalTrials":519,"cells":3091},{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3102,"PHASE4":3104,"NA":3106},{"trials":3093,"activeCount":8},[],{"trials":3095,"activeCount":8},[],{"trials":3097,"activeCount":8},[3098],{"nctId":1315,"briefTitle":1316,"status":130,"phases":3099,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":3100,"interventions":3101},[40],[32],[1322,1323,1324,1325,1326,1306],{"trials":3103,"activeCount":8},[],{"trials":3105,"activeCount":8},[],{"trials":3107,"activeCount":8},[],{"intervention":1325,"totalTrials":519,"cells":3109},{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3111,"activeCount":8},[],{"trials":3113,"activeCount":8},[],{"trials":3115,"activeCount":8},[3116],{"nctId":1315,"briefTitle":1316,"status":130,"phases":3117,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":3118,"interventions":3119},[40],[32],[1322,1323,1324,1325,1326,1306],{"trials":3121,"activeCount":8},[],{"trials":3123,"activeCount":8},[],{"trials":3125,"activeCount":8},[],{"intervention":1326,"totalTrials":519,"cells":3127},{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3132,"PHASE3":3138,"PHASE4":3140,"NA":3142},{"trials":3129,"activeCount":8},[],{"trials":3131,"activeCount":8},[],{"trials":3133,"activeCount":8},[3134],{"nctId":1315,"briefTitle":1316,"status":130,"phases":3135,"primaryCompletion":746,"completion":746,"start":1318,"enrollment":1319,"conditions":3136,"interventions":3137},[40],[32],[1322,1323,1324,1325,1326,1306],{"trials":3139,"activeCount":8},[],{"trials":3141,"activeCount":8},[],{"trials":3143,"activeCount":8},[],{"intervention":1194,"totalTrials":519,"cells":3145},{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3156,"PHASE4":3158,"NA":3160},{"trials":3147,"activeCount":8},[],{"trials":3149,"activeCount":8},[],{"trials":3151,"activeCount":8},[3152],{"nctId":1183,"briefTitle":1184,"status":56,"phases":3153,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":3154,"interventions":3155},[39,40],[1191],[1193,1194,1195,1122,1181],{"trials":3157,"activeCount":8},[],{"trials":3159,"activeCount":8},[],{"trials":3161,"activeCount":8},[],{"intervention":1195,"totalTrials":519,"cells":3163},{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3168,"PHASE3":3174,"PHASE4":3176,"NA":3178},{"trials":3165,"activeCount":8},[],{"trials":3167,"activeCount":8},[],{"trials":3169,"activeCount":8},[3170],{"nctId":1183,"briefTitle":1184,"status":56,"phases":3171,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":3172,"interventions":3173},[39,40],[1191],[1193,1194,1195,1122,1181],{"trials":3175,"activeCount":8},[],{"trials":3177,"activeCount":8},[],{"trials":3179,"activeCount":8},[],{"intervention":3181,"totalTrials":519,"cells":3182},"IFN beta 1a 44 mcg TIW",{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3184,"activeCount":8},[],{"trials":3186,"activeCount":8},[],{"trials":3188,"activeCount":8},[3189],{"nctId":3190,"briefTitle":3191,"status":56,"phases":3192,"primaryCompletion":3193,"completion":3193,"start":3194,"enrollment":3195,"conditions":3196,"interventions":3197},"NCT01514370","Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a",[40],"2016-03-31","2012-04-30",80,[17],[3181,3198],"Curcumin",{"trials":3200,"activeCount":8},[],{"trials":3202,"activeCount":8},[],{"trials":3204,"activeCount":8},[],{"intervention":3198,"totalTrials":519,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3208,"activeCount":8},[],{"trials":3210,"activeCount":8},[],{"trials":3212,"activeCount":8},[3213],{"nctId":3190,"briefTitle":3191,"status":56,"phases":3214,"primaryCompletion":3193,"completion":3193,"start":3194,"enrollment":3195,"conditions":3215,"interventions":3216},[40],[17],[3181,3198],{"trials":3218,"activeCount":8},[],{"trials":3220,"activeCount":8},[],{"trials":3222,"activeCount":8},[],{"intervention":1636,"totalTrials":519,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3226,"activeCount":8},[],{"trials":3228,"activeCount":8},[],{"trials":3230,"activeCount":8},[3231],{"nctId":1627,"briefTitle":1628,"status":56,"phases":3232,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":3233,"interventions":3234},[40],[1634],[1636,1520,1637,1618,1638],{"trials":3236,"activeCount":8},[],{"trials":3238,"activeCount":8},[],{"trials":3240,"activeCount":8},[],{"intervention":1637,"totalTrials":519,"cells":3242},{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3247,"PHASE3":3253,"PHASE4":3255,"NA":3257},{"trials":3244,"activeCount":8},[],{"trials":3246,"activeCount":8},[],{"trials":3248,"activeCount":8},[3249],{"nctId":1627,"briefTitle":1628,"status":56,"phases":3250,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":3251,"interventions":3252},[40],[1634],[1636,1520,1637,1618,1638],{"trials":3254,"activeCount":8},[],{"trials":3256,"activeCount":8},[],{"trials":3258,"activeCount":8},[],{"intervention":3260,"totalTrials":519,"cells":3261},"Sprifermin (AS902330) 10 mcg",{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3263,"activeCount":8},[],{"trials":3265,"activeCount":8},[],{"trials":3267,"activeCount":8},[3268],{"nctId":3269,"briefTitle":3270,"status":130,"phases":3271,"primaryCompletion":121,"completion":121,"start":3272,"enrollment":3273,"conditions":3274,"interventions":3276},"NCT01066871","Sprifermin (AS902330) in Cartilage Injury Repair (CIR)",[40],"2010-03",74,[3275],"Isolated Cartilage Injury of the Knee",[3260,3277,3278],"Sprifermin (AS902330) 30 mcg","Sprifermin (AS902330) 100 mcg",{"trials":3280,"activeCount":8},[],{"trials":3282,"activeCount":8},[],{"trials":3284,"activeCount":8},[],{"intervention":3277,"totalTrials":519,"cells":3286},{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3297,"PHASE4":3299,"NA":3301},{"trials":3288,"activeCount":8},[],{"trials":3290,"activeCount":8},[],{"trials":3292,"activeCount":8},[3293],{"nctId":3269,"briefTitle":3270,"status":130,"phases":3294,"primaryCompletion":121,"completion":121,"start":3272,"enrollment":3273,"conditions":3295,"interventions":3296},[40],[3275],[3260,3277,3278],{"trials":3298,"activeCount":8},[],{"trials":3300,"activeCount":8},[],{"trials":3302,"activeCount":8},[],{"intervention":3278,"totalTrials":519,"cells":3304},{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3306,"activeCount":8},[],{"trials":3308,"activeCount":8},[],{"trials":3310,"activeCount":8},[3311],{"nctId":3269,"briefTitle":3270,"status":130,"phases":3312,"primaryCompletion":121,"completion":121,"start":3272,"enrollment":3273,"conditions":3313,"interventions":3314},[40],[3275],[3260,3277,3278],{"trials":3316,"activeCount":8},[],{"trials":3318,"activeCount":8},[],{"trials":3320,"activeCount":8},[],{"intervention":1699,"totalTrials":519,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3324,"activeCount":8},[],{"trials":3326,"activeCount":8},[],{"trials":3328,"activeCount":8},[3329],{"nctId":1692,"briefTitle":1693,"status":56,"phases":3330,"primaryCompletion":112,"completion":112,"start":1160,"enrollment":1695,"conditions":3331,"interventions":3332},[39,40],[1697],[1141,1683,1699],{"trials":3334,"activeCount":8},[],{"trials":3336,"activeCount":8},[],{"trials":3338,"activeCount":8},[],{"intervention":3340,"totalTrials":519,"cells":3341},"Biltricide (racemate praziquantel) oral",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3343,"activeCount":8},[],{"trials":3345,"activeCount":8},[],{"trials":3347,"activeCount":8},[3348],{"nctId":3349,"briefTitle":3350,"status":56,"phases":3351,"primaryCompletion":1175,"completion":3352,"start":3353,"enrollment":3354,"conditions":3355,"interventions":3356},"NCT02806232","An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)",[40],"2018-11-17","2016-06-12",444,[1944],[3340,3357,3358],"Racemate Praziquantel ODT","Levo Praziquantel ODT",{"trials":3360,"activeCount":8},[],{"trials":3362,"activeCount":8},[],{"trials":3364,"activeCount":8},[],{"intervention":3357,"totalTrials":519,"cells":3366},{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3371,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3368,"activeCount":8},[],{"trials":3370,"activeCount":8},[],{"trials":3372,"activeCount":8},[3373],{"nctId":3349,"briefTitle":3350,"status":56,"phases":3374,"primaryCompletion":1175,"completion":3352,"start":3353,"enrollment":3354,"conditions":3375,"interventions":3376},[40],[1944],[3340,3357,3358],{"trials":3378,"activeCount":8},[],{"trials":3380,"activeCount":8},[],{"trials":3382,"activeCount":8},[],{"intervention":3358,"totalTrials":519,"cells":3384},{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3389,"PHASE3":3395,"PHASE4":3397,"NA":3399},{"trials":3386,"activeCount":8},[],{"trials":3388,"activeCount":8},[],{"trials":3390,"activeCount":8},[3391],{"nctId":3349,"briefTitle":3350,"status":56,"phases":3392,"primaryCompletion":1175,"completion":3352,"start":3353,"enrollment":3354,"conditions":3393,"interventions":3394},[40],[1944],[3340,3357,3358],{"trials":3396,"activeCount":8},[],{"trials":3398,"activeCount":8},[],{"trials":3400,"activeCount":8},[],{"intervention":1521,"totalTrials":519,"cells":3402},{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3413,"PHASE4":3415,"NA":3417},{"trials":3404,"activeCount":8},[],{"trials":3406,"activeCount":8},[],{"trials":3408,"activeCount":8},[3409],{"nctId":1512,"briefTitle":1513,"status":56,"phases":3410,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":1517,"conditions":3411,"interventions":3412},[40],[14],[1493,1520,1521],{"trials":3414,"activeCount":8},[],{"trials":3416,"activeCount":8},[],{"trials":3418,"activeCount":8},[],{"intervention":1208,"totalTrials":519,"cells":3420},{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3422,"activeCount":8},[],{"trials":3424,"activeCount":8},[],{"trials":3426,"activeCount":8},[3427],{"nctId":1197,"briefTitle":1198,"status":56,"phases":3428,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":3429,"interventions":3430},[40],[1205,1206],[1208,1209,1122,1210],{"trials":3432,"activeCount":8},[],{"trials":3434,"activeCount":8},[],{"trials":3436,"activeCount":8},[],{"intervention":1209,"totalTrials":519,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":8},[],{"trials":3442,"activeCount":8},[],{"trials":3444,"activeCount":8},[3445],{"nctId":1197,"briefTitle":1198,"status":56,"phases":3446,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":3447,"interventions":3448},[40],[1205,1206],[1208,1209,1122,1210],{"trials":3450,"activeCount":8},[],{"trials":3452,"activeCount":8},[],{"trials":3454,"activeCount":8},[],{"intervention":3456,"totalTrials":519,"cells":3457},"VigantOL oil plus interferon beta-1a",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3459,"activeCount":8},[],{"trials":3461,"activeCount":8},[],{"trials":3463,"activeCount":8},[3464],{"nctId":3465,"briefTitle":3466,"status":56,"phases":3467,"primaryCompletion":3468,"completion":3469,"start":1147,"enrollment":3470,"conditions":3471,"interventions":3473},"NCT01285401","Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment",[40],"2015-04","2015-05",260,[3472],"Relapsing-Remitting Multiple Sclerosis",[3456,3474],"Interferon beta-1a (Rebif®) alone",{"trials":3476,"activeCount":8},[],{"trials":3478,"activeCount":8},[],{"trials":3480,"activeCount":8},[],{"intervention":3474,"totalTrials":519,"cells":3482},{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3493,"PHASE4":3495,"NA":3497},{"trials":3484,"activeCount":8},[],{"trials":3486,"activeCount":8},[],{"trials":3488,"activeCount":8},[3489],{"nctId":3465,"briefTitle":3466,"status":56,"phases":3490,"primaryCompletion":3468,"completion":3469,"start":1147,"enrollment":3470,"conditions":3491,"interventions":3492},[40],[3472],[3456,3474],{"trials":3494,"activeCount":8},[],{"trials":3496,"activeCount":8},[],{"trials":3498,"activeCount":8},[],{"intervention":3500,"totalTrials":519,"cells":3501},"EMD 525797 250 mg",{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3503,"activeCount":8},[],{"trials":3505,"activeCount":8},[],{"trials":3507,"activeCount":8},[3508],{"nctId":3509,"briefTitle":3510,"status":56,"phases":3511,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":3512,"interventions":3513},"NCT01008475","EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer",[39,40],[1697],[3500,3514,3515,3516,1141,3517],"EMD 525797 500 mg","EMD 525797 750 mg","EMD 525797 1000 mg","Irinotecan",{"trials":3519,"activeCount":8},[],{"trials":3521,"activeCount":8},[],{"trials":3523,"activeCount":8},[],{"intervention":3514,"totalTrials":519,"cells":3525},{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3527,"activeCount":8},[],{"trials":3529,"activeCount":8},[],{"trials":3531,"activeCount":8},[3532],{"nctId":3509,"briefTitle":3510,"status":56,"phases":3533,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":3534,"interventions":3535},[39,40],[1697],[3500,3514,3515,3516,1141,3517],{"trials":3537,"activeCount":8},[],{"trials":3539,"activeCount":8},[],{"trials":3541,"activeCount":8},[],{"intervention":3515,"totalTrials":519,"cells":3543},{"EARLY_PHASE1":3544,"PHASE1":3546,"PHASE2":3548,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3545,"activeCount":8},[],{"trials":3547,"activeCount":8},[],{"trials":3549,"activeCount":8},[3550],{"nctId":3509,"briefTitle":3510,"status":56,"phases":3551,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":3552,"interventions":3553},[39,40],[1697],[3500,3514,3515,3516,1141,3517],{"trials":3555,"activeCount":8},[],{"trials":3557,"activeCount":8},[],{"trials":3559,"activeCount":8},[],{"intervention":3516,"totalTrials":519,"cells":3561},{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3563,"activeCount":8},[],{"trials":3565,"activeCount":8},[],{"trials":3567,"activeCount":8},[3568],{"nctId":3509,"briefTitle":3510,"status":56,"phases":3569,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":3570,"interventions":3571},[39,40],[1697],[3500,3514,3515,3516,1141,3517],{"trials":3573,"activeCount":8},[],{"trials":3575,"activeCount":8},[],{"trials":3577,"activeCount":8},[],{"intervention":3517,"totalTrials":519,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3581,"activeCount":8},[],{"trials":3583,"activeCount":8},[],{"trials":3585,"activeCount":8},[3586],{"nctId":3509,"briefTitle":3510,"status":56,"phases":3587,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":3588,"interventions":3589},[39,40],[1697],[3500,3514,3515,3516,1141,3517],{"trials":3591,"activeCount":8},[],{"trials":3593,"activeCount":8},[],{"trials":3595,"activeCount":8},[],{"intervention":2626,"totalTrials":519,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3599,"activeCount":8},[],{"trials":3601,"activeCount":8},[],{"trials":3603,"activeCount":8},[3604],{"nctId":2618,"briefTitle":2619,"status":56,"phases":3605,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":2022,"conditions":3606,"interventions":3607},[39,40],[2611],[2626,2627,2628,1193,2629],{"trials":3609,"activeCount":8},[],{"trials":3611,"activeCount":8},[],{"trials":3613,"activeCount":8},[],{"intervention":2627,"totalTrials":519,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3617,"activeCount":8},[],{"trials":3619,"activeCount":8},[],{"trials":3621,"activeCount":8},[3622],{"nctId":2618,"briefTitle":2619,"status":56,"phases":3623,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":2022,"conditions":3624,"interventions":3625},[39,40],[2611],[2626,2627,2628,1193,2629],{"trials":3627,"activeCount":8},[],{"trials":3629,"activeCount":8},[],{"trials":3631,"activeCount":8},[],{"intervention":2628,"totalTrials":519,"cells":3633},{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3635,"activeCount":8},[],{"trials":3637,"activeCount":8},[],{"trials":3639,"activeCount":8},[3640],{"nctId":2618,"briefTitle":2619,"status":56,"phases":3641,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":2022,"conditions":3642,"interventions":3643},[39,40],[2611],[2626,2627,2628,1193,2629],{"trials":3645,"activeCount":8},[],{"trials":3647,"activeCount":8},[],{"trials":3649,"activeCount":8},[],{"intervention":2629,"totalTrials":519,"cells":3651},{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3656,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3653,"activeCount":8},[],{"trials":3655,"activeCount":8},[],{"trials":3657,"activeCount":8},[3658],{"nctId":2618,"briefTitle":2619,"status":56,"phases":3659,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":2022,"conditions":3660,"interventions":3661},[39,40],[2611],[2626,2627,2628,1193,2629],{"trials":3663,"activeCount":8},[],{"trials":3665,"activeCount":8},[],{"trials":3667,"activeCount":8},[],{"intervention":3669,"totalTrials":519,"cells":3670},"IFN beta-1a",{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3672,"activeCount":8},[],{"trials":3674,"activeCount":8},[],{"trials":3676,"activeCount":8},[3677],{"nctId":3678,"briefTitle":3679,"status":130,"phases":3680,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":3683,"conditions":3684,"interventions":3685},"NCT03387046","A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)",[40],"2019-01-11","2018-03-26",7,[26],[3669,3686],"Methylprednisolone",{"trials":3688,"activeCount":8},[],{"trials":3690,"activeCount":8},[],{"trials":3692,"activeCount":8},[],{"intervention":3686,"totalTrials":519,"cells":3694},{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3696,"activeCount":8},[],{"trials":3698,"activeCount":8},[],{"trials":3700,"activeCount":8},[3701],{"nctId":3678,"briefTitle":3679,"status":130,"phases":3702,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":3683,"conditions":3703,"interventions":3704},[40],[26],[3669,3686],{"trials":3706,"activeCount":8},[],{"trials":3708,"activeCount":8},[],{"trials":3710,"activeCount":8},[],{"intervention":1220,"totalTrials":519,"cells":3712},{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3723,"PHASE4":3725,"NA":3727},{"trials":3714,"activeCount":8},[],{"trials":3716,"activeCount":8},[],{"trials":3718,"activeCount":8},[3719],{"nctId":1212,"briefTitle":1213,"status":56,"phases":3720,"primaryCompletion":856,"completion":1215,"start":1216,"enrollment":1217,"conditions":3721,"interventions":3722},[40],[1206],[1141,1122,1220],{"trials":3724,"activeCount":8},[],{"trials":3726,"activeCount":8},[],{"trials":3728,"activeCount":8},[],{"intervention":1475,"totalTrials":519,"cells":3730},{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3741,"PHASE4":3743,"NA":3745},{"trials":3732,"activeCount":8},[],{"trials":3734,"activeCount":8},[],{"trials":3736,"activeCount":8},[3737],{"nctId":1469,"briefTitle":1470,"status":130,"phases":3738,"primaryCompletion":1472,"completion":1472,"start":155,"enrollment":313,"conditions":3739,"interventions":3740},[40],[14,32],[1450,1475],{"trials":3742,"activeCount":8},[],{"trials":3744,"activeCount":8},[],{"trials":3746,"activeCount":8},[],{"intervention":1335,"totalTrials":519,"cells":3748},{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3759,"PHASE4":3761,"NA":3763},{"trials":3750,"activeCount":8},[],{"trials":3752,"activeCount":8},[],{"trials":3754,"activeCount":8},[3755],{"nctId":1328,"briefTitle":1329,"status":56,"phases":3756,"primaryCompletion":232,"completion":232,"start":1331,"enrollment":1332,"conditions":3757,"interventions":3758},[40],[14],[1335,1336,1337,1338,1306],{"trials":3760,"activeCount":8},[],{"trials":3762,"activeCount":8},[],{"trials":3764,"activeCount":8},[],{"intervention":1336,"totalTrials":519,"cells":3766},{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3777,"PHASE4":3779,"NA":3781},{"trials":3768,"activeCount":8},[],{"trials":3770,"activeCount":8},[],{"trials":3772,"activeCount":8},[3773],{"nctId":1328,"briefTitle":1329,"status":56,"phases":3774,"primaryCompletion":232,"completion":232,"start":1331,"enrollment":1332,"conditions":3775,"interventions":3776},[40],[14],[1335,1336,1337,1338,1306],{"trials":3778,"activeCount":8},[],{"trials":3780,"activeCount":8},[],{"trials":3782,"activeCount":8},[],{"intervention":1337,"totalTrials":519,"cells":3784},{"EARLY_PHASE1":3785,"PHASE1":3787,"PHASE2":3789,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3786,"activeCount":8},[],{"trials":3788,"activeCount":8},[],{"trials":3790,"activeCount":8},[3791],{"nctId":1328,"briefTitle":1329,"status":56,"phases":3792,"primaryCompletion":232,"completion":232,"start":1331,"enrollment":1332,"conditions":3793,"interventions":3794},[40],[14],[1335,1336,1337,1338,1306],{"trials":3796,"activeCount":8},[],{"trials":3798,"activeCount":8},[],{"trials":3800,"activeCount":8},[],{"intervention":1338,"totalTrials":519,"cells":3802},{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3807,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3804,"activeCount":8},[],{"trials":3806,"activeCount":8},[],{"trials":3808,"activeCount":8},[3809],{"nctId":1328,"briefTitle":1329,"status":56,"phases":3810,"primaryCompletion":232,"completion":232,"start":1331,"enrollment":1332,"conditions":3811,"interventions":3812},[40],[14],[1335,1336,1337,1338,1306],{"trials":3814,"activeCount":8},[],{"trials":3816,"activeCount":8},[],{"trials":3818,"activeCount":8},[],{"intervention":3820,"totalTrials":519,"cells":3821},"ATX-MS-1467",{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3823,"activeCount":8},[],{"trials":3825,"activeCount":8},[],{"trials":3827,"activeCount":8},[3828],{"nctId":3829,"briefTitle":3830,"status":56,"phases":3831,"primaryCompletion":187,"completion":187,"start":3832,"enrollment":3833,"conditions":3834,"interventions":3835},"NCT01973491","ATX-MS-1467 in Multiple Sclerosis",[40],"2014-02-28",37,[17],[3820],{"trials":3837,"activeCount":8},[],{"trials":3839,"activeCount":8},[],{"trials":3841,"activeCount":8},[],{"intervention":1290,"totalTrials":519,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3845,"activeCount":8},[],{"trials":3847,"activeCount":8},[],{"trials":3849,"activeCount":8},[3850],{"nctId":1284,"briefTitle":1285,"status":56,"phases":3851,"primaryCompletion":1147,"completion":1236,"start":303,"enrollment":337,"conditions":3852,"interventions":3853},[40],[1288],[1265,1265,1247,1290],{"trials":3855,"activeCount":8},[],{"trials":3857,"activeCount":8},[],{"trials":3859,"activeCount":8},[],{"intervention":3861,"totalTrials":287,"cells":3862},"Pimasertib",{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3864,"activeCount":8},[],{"trials":3866,"activeCount":8},[3867,3878],{"nctId":3868,"briefTitle":3869,"status":130,"phases":3870,"primaryCompletion":3871,"completion":3871,"start":3872,"enrollment":3873,"conditions":3874,"interventions":3877},"NCT01668017","A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy",[39],"2015-05-31","2012-09-30",26,[3875,3876],"Advanced Solid Tumors","Hepatocellular Carcinoma",[3861,3861,3861,3861,3861],{"nctId":3879,"briefTitle":3880,"status":56,"phases":3881,"primaryCompletion":3882,"completion":3882,"start":3883,"enrollment":279,"conditions":3884,"interventions":3886},"NCT01713036","Oral Bioavailability and Mass Balance Trial With Pimasertib",[39],"2014-07-31","2012-11-30",[3885],"Locally Advanced or Metastatic Solid Tumors",[3861],{"trials":3888,"activeCount":8},[],{"trials":3890,"activeCount":8},[],{"trials":3892,"activeCount":8},[],{"trials":3894,"activeCount":8},[],{"intervention":3896,"totalTrials":287,"cells":3897},"Evobrutinib",{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3899,"activeCount":8},[],{"trials":3901,"activeCount":8},[3902,3909],{"nctId":3903,"briefTitle":3904,"status":56,"phases":3905,"primaryCompletion":3906,"completion":3906,"start":1175,"enrollment":279,"conditions":3907,"interventions":3908},"NCT03725072","Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib",[39],"2018-12-05",[20],[3896],{"nctId":3910,"briefTitle":3911,"status":56,"phases":3912,"primaryCompletion":3913,"completion":3913,"start":3914,"enrollment":1482,"conditions":3915,"interventions":3917},"NCT03436394","Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)",[39],"2019-02-22","2018-03-21",[3916],"Renal Impairment",[3896],{"trials":3919,"activeCount":8},[],{"trials":3921,"activeCount":8},[],{"trials":3923,"activeCount":8},[],{"trials":3925,"activeCount":8},[],{"intervention":3927,"totalTrials":287,"cells":3928},"Cladribine",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3930,"activeCount":8},[],{"trials":3932,"activeCount":8},[3933,3941],{"nctId":3934,"briefTitle":3935,"status":56,"phases":3936,"primaryCompletion":2219,"completion":2219,"start":303,"enrollment":3937,"conditions":3938,"interventions":3939},"NCT00938366","Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects",[39],18,[17],[3927,3940],"Pantoprazole",{"nctId":3942,"briefTitle":3943,"status":56,"phases":3944,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":3948,"conditions":3949,"interventions":3951},"NCT03745144","Effects of Cladribine Tablets on the PK of Microgynon®",[39],"2022-09-02","2022-09-16","2019-01-17",28,[3950],"Relapsing Multiple Sclerosis (RMS)",[3927,3952],"Microgynon®",{"trials":3954,"activeCount":8},[],{"trials":3956,"activeCount":8},[],{"trials":3958,"activeCount":8},[],{"trials":3960,"activeCount":8},[],{"intervention":3962,"totalTrials":287,"cells":3963},"Cysticide",{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3987,"PHASE3":3989,"PHASE4":3991,"NA":3993},{"trials":3965,"activeCount":8},[],{"trials":3967,"activeCount":8},[3968,3978],{"nctId":3969,"briefTitle":3970,"status":56,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":3973,"enrollment":3974,"conditions":3975,"interventions":3976},"NCT02271984","Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers",[39],"2014-12-31","2014-10-31",36,[20],[3977,3962,3977,3977,3977,3977],"MSC2499550A",{"nctId":3979,"briefTitle":3980,"status":56,"phases":3981,"primaryCompletion":3982,"completion":1440,"start":3982,"enrollment":60,"conditions":3983,"interventions":3984},"NCT02325713","Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers",[39],"2015-01",[20],[3985,3962,3986,3986,3986,3962],"Oral dispersible tablet of praziquantel","ODT-PZQ",{"trials":3988,"activeCount":8},[],{"trials":3990,"activeCount":8},[],{"trials":3992,"activeCount":8},[],{"trials":3994,"activeCount":8},[],{"intervention":3996,"totalTrials":287,"cells":3997},"AS902330",{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":3999,"activeCount":8},[],{"trials":4001,"activeCount":8},[4002,4010],{"nctId":4003,"briefTitle":4004,"status":56,"phases":4005,"primaryCompletion":122,"completion":4006,"start":1505,"enrollment":1227,"conditions":4007,"interventions":4009},"NCT00911469","Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement",[39],"2010-06",[4008],"Knee Osteoarthritis",[3996],{"nctId":4011,"briefTitle":4012,"status":56,"phases":4013,"primaryCompletion":1472,"completion":4014,"start":1134,"enrollment":4015,"conditions":4016,"interventions":4017},"NCT01033994","A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery",[39],"2010-12",192,[4008],[3996],{"trials":4019,"activeCount":8},[],{"trials":4021,"activeCount":8},[],{"trials":4023,"activeCount":8},[],{"trials":4025,"activeCount":8},[],{"intervention":4027,"totalTrials":287,"cells":4028},"Metformin\u002FGliclazide Fixed Combination",{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4051,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4030,"activeCount":8},[],{"trials":4032,"activeCount":8},[4033,4041],{"nctId":4034,"briefTitle":4035,"status":56,"phases":4036,"primaryCompletion":4037,"completion":4037,"start":4038,"enrollment":21,"conditions":4039,"interventions":4040},"NCT03467971","A Study to Assess the Food Effect on Bioavailability of Metformin\u002FGliclazide in Healthy Participants",[39],"2018-04-22","2018-03-06",[20],[4027],{"nctId":4042,"briefTitle":4043,"status":56,"phases":4044,"primaryCompletion":4045,"completion":4045,"start":4046,"enrollment":1217,"conditions":4047,"interventions":4048},"NCT03467945","Bioequivalence and Drug - Drug Interaction Study of Metformin\u002FGliclazide in Healthy Participants",[39],"2018-04-29","2018-02-16",[20],[4027,4049,4050],"Metformin","Gliclazide",{"trials":4052,"activeCount":8},[],{"trials":4054,"activeCount":8},[],{"trials":4056,"activeCount":8},[],{"trials":4058,"activeCount":8},[],{"intervention":4060,"totalTrials":287,"cells":4061},"EMD 521873",{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4083,"PHASE3":4085,"PHASE4":4087,"NA":4089},{"trials":4063,"activeCount":8},[],{"trials":4065,"activeCount":8},[4066,4074],{"nctId":4067,"briefTitle":4068,"status":56,"phases":4069,"primaryCompletion":1147,"completion":4070,"start":1706,"enrollment":2609,"conditions":4071,"interventions":4073},"NCT01032681","EMD 521873 in Advanced Solid Tumors, MTD Finding",[39],"2012-01",[4072],"Non-Hodgkin Lymphoma",[4060,4060,4060],{"nctId":4075,"briefTitle":4076,"status":56,"phases":4077,"primaryCompletion":1147,"completion":2089,"start":233,"enrollment":4078,"conditions":4079,"interventions":4082},"NCT00879866","EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)",[39],15,[4080,4081],"Lung Cancer","Non Small Cell Lung Cancer",[4060],{"trials":4084,"activeCount":8},[],{"trials":4086,"activeCount":8},[],{"trials":4088,"activeCount":8},[],{"trials":4090,"activeCount":8},[],{"intervention":4092,"totalTrials":287,"cells":4093},"EMD 525797",{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4114,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4095,"activeCount":8},[],{"trials":4097,"activeCount":8},[4098,4106],{"nctId":4099,"briefTitle":4100,"status":56,"phases":4101,"primaryCompletion":4102,"completion":4102,"start":1160,"enrollment":604,"conditions":4103,"interventions":4105},"NCT00848510","EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases",[39],"2013-11",[4104],"Colorectal and Ovarian Cancer Patients With Liver Metastases",[4092],{"nctId":4107,"briefTitle":4108,"status":56,"phases":4109,"primaryCompletion":2384,"completion":745,"start":1134,"enrollment":3873,"conditions":4110,"interventions":4113},"NCT00958477","A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer",[39],[4111,4112],"Prostate Cancer","Bone Metastases",[4092],{"trials":4115,"activeCount":8},[],{"trials":4117,"activeCount":8},[],{"trials":4119,"activeCount":8},[],{"trials":4121,"activeCount":8},[],{"intervention":4123,"totalTrials":287,"cells":4124},"M6495",{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4147,"PHASE3":4149,"PHASE4":4151,"NA":4153},{"trials":4126,"activeCount":8},[],{"trials":4128,"activeCount":8},[4129,4138],{"nctId":4130,"briefTitle":4131,"status":56,"phases":4132,"primaryCompletion":4133,"completion":4133,"start":4134,"enrollment":60,"conditions":4135,"interventions":4137},"NCT03583346","Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)",[39],"2019-07-31","2018-08-23",[4136],"Osteoarthritis, Knee",[4123],{"nctId":4139,"briefTitle":4140,"status":56,"phases":4141,"primaryCompletion":4142,"completion":4142,"start":4143,"enrollment":4144,"conditions":4145,"interventions":4146},"NCT03224702","First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers",[39],"2018-08-06","2017-09-04",54,[20],[4123],{"trials":4148,"activeCount":8},[],{"trials":4150,"activeCount":8},[],{"trials":4152,"activeCount":8},[],{"trials":4154,"activeCount":8},[],{"intervention":4156,"totalTrials":519,"cells":4157},"Drug",{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4169,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4159,"activeCount":8},[],{"trials":4161,"activeCount":8},[4162],{"nctId":4163,"briefTitle":4164,"status":130,"phases":4165,"primaryCompletion":1237,"completion":1237,"start":856,"enrollment":519,"conditions":4166,"interventions":4168},"NCT01558687","Cilengitide Imaging Trial in Glioblastoma",[39],[4167],"Supratentorial Newly Diagnosed Inoperable Gliobastoma",[4156],{"trials":4170,"activeCount":8},[],{"trials":4172,"activeCount":8},[],{"trials":4174,"activeCount":8},[],{"trials":4176,"activeCount":8},[],{"intervention":4178,"totalTrials":519,"cells":4179},"EMD 640744",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4190,"PHASE3":4192,"PHASE4":4194,"NA":4196},{"trials":4181,"activeCount":8},[],{"trials":4183,"activeCount":8},[4184],{"nctId":4185,"briefTitle":4186,"status":56,"phases":4187,"primaryCompletion":857,"completion":499,"start":312,"enrollment":2467,"conditions":4188,"interventions":4189},"NCT01012102","EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors",[39],[3875],[4178,4178,4178],{"trials":4191,"activeCount":8},[],{"trials":4193,"activeCount":8},[],{"trials":4195,"activeCount":8},[],{"trials":4197,"activeCount":8},[],{"intervention":4199,"totalTrials":519,"cells":4200},"cilengitide 2000mg",{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4219},{"trials":4202,"activeCount":8},[],{"trials":4204,"activeCount":8},[4205],{"nctId":4206,"briefTitle":4207,"status":56,"phases":4208,"primaryCompletion":1271,"completion":1271,"start":4070,"enrollment":60,"conditions":4209,"interventions":4210},"NCT01504165","Pharmacokinetics in Subjects With Renal Impairment",[39],[3916],[4199,4199,4199,4211,4212],"cilengitide 1000mg","cilengitide > 1000mg and up to 2000mg",{"trials":4214,"activeCount":8},[],{"trials":4216,"activeCount":8},[],{"trials":4218,"activeCount":8},[],{"trials":4220,"activeCount":8},[],{"intervention":4211,"totalTrials":519,"cells":4222},{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4231,"PHASE3":4233,"PHASE4":4235,"NA":4237},{"trials":4224,"activeCount":8},[],{"trials":4226,"activeCount":8},[4227],{"nctId":4206,"briefTitle":4207,"status":56,"phases":4228,"primaryCompletion":1271,"completion":1271,"start":4070,"enrollment":60,"conditions":4229,"interventions":4230},[39],[3916],[4199,4199,4199,4211,4212],{"trials":4232,"activeCount":8},[],{"trials":4234,"activeCount":8},[],{"trials":4236,"activeCount":8},[],{"trials":4238,"activeCount":8},[],{"intervention":4212,"totalTrials":519,"cells":4240},{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4242,"activeCount":8},[],{"trials":4244,"activeCount":8},[4245],{"nctId":4206,"briefTitle":4207,"status":56,"phases":4246,"primaryCompletion":1271,"completion":1271,"start":4070,"enrollment":60,"conditions":4247,"interventions":4248},[39],[3916],[4199,4199,4199,4211,4212],{"trials":4250,"activeCount":8},[],{"trials":4252,"activeCount":8},[],{"trials":4254,"activeCount":8},[],{"trials":4256,"activeCount":8},[],{"intervention":4258,"totalTrials":519,"cells":4259},"Sym004",{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4273,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4261,"activeCount":8},[],{"trials":4263,"activeCount":8},[4264],{"nctId":4265,"briefTitle":4266,"status":56,"phases":4267,"primaryCompletion":4268,"completion":4268,"start":4269,"enrollment":4270,"conditions":4271,"interventions":4272},"NCT01955473","Japanese Phase 1 Trial of Sym004 in Solid Tumors",[39],"2015-10-31","2013-10-31",51,[34],[4258],{"trials":4274,"activeCount":8},[],{"trials":4276,"activeCount":8},[],{"trials":4278,"activeCount":8},[],{"trials":4280,"activeCount":8},[],{"intervention":4282,"totalTrials":519,"cells":4283},"M7583",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4296,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4285,"activeCount":8},[],{"trials":4287,"activeCount":8},[4288],{"nctId":4289,"briefTitle":4290,"status":56,"phases":4291,"primaryCompletion":4292,"completion":4292,"start":4293,"enrollment":3937,"conditions":4294,"interventions":4295},"NCT03297983","M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule",[39],"2017-12-06","2017-10-09",[20],[4282],{"trials":4297,"activeCount":8},[],{"trials":4299,"activeCount":8},[],{"trials":4301,"activeCount":8},[],{"trials":4303,"activeCount":8},[],{"intervention":4305,"totalTrials":519,"cells":4306},"Liquid pergoveris",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4319,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4308,"activeCount":8},[],{"trials":4310,"activeCount":8},[4311],{"nctId":4312,"briefTitle":4313,"status":56,"phases":4314,"primaryCompletion":4268,"completion":4268,"start":4315,"enrollment":337,"conditions":4316,"interventions":4317},"NCT02317809","Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects",[39],"2015-01-31",[20],[4305,4318],"Freeze-dried pergoveris",{"trials":4320,"activeCount":8},[],{"trials":4322,"activeCount":8},[],{"trials":4324,"activeCount":8},[],{"trials":4326,"activeCount":8},[],{"intervention":4318,"totalTrials":519,"cells":4328},{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4337,"PHASE3":4339,"PHASE4":4341,"NA":4343},{"trials":4330,"activeCount":8},[],{"trials":4332,"activeCount":8},[4333],{"nctId":4312,"briefTitle":4313,"status":56,"phases":4334,"primaryCompletion":4268,"completion":4268,"start":4315,"enrollment":337,"conditions":4335,"interventions":4336},[39],[20],[4305,4318],{"trials":4338,"activeCount":8},[],{"trials":4340,"activeCount":8},[],{"trials":4342,"activeCount":8},[],{"trials":4344,"activeCount":8},[],{"intervention":4346,"totalTrials":519,"cells":4347},"Test GIR",{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4362,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4349,"activeCount":8},[],{"trials":4351,"activeCount":8},[4352],{"nctId":4353,"briefTitle":4354,"status":56,"phases":4355,"primaryCompletion":4356,"completion":4356,"start":4357,"enrollment":4358,"conditions":4359,"interventions":4360},"NCT03393208","Glucophage Immediate Release (GIR) China Bioequivalence Study",[39],"2018-01-29","2018-01-10",44,[20],[4346,4361],"Reference GIR",{"trials":4363,"activeCount":8},[],{"trials":4365,"activeCount":8},[],{"trials":4367,"activeCount":8},[],{"trials":4369,"activeCount":8},[],{"intervention":4361,"totalTrials":519,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4373,"activeCount":8},[],{"trials":4375,"activeCount":8},[4376],{"nctId":4353,"briefTitle":4354,"status":56,"phases":4377,"primaryCompletion":4356,"completion":4356,"start":4357,"enrollment":4358,"conditions":4378,"interventions":4379},[39],[20],[4346,4361],{"trials":4381,"activeCount":8},[],{"trials":4383,"activeCount":8},[],{"trials":4385,"activeCount":8},[],{"trials":4387,"activeCount":8},[],{"intervention":2581,"totalTrials":519,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4391,"activeCount":8},[],{"trials":4393,"activeCount":8},[4394],{"nctId":2574,"briefTitle":2575,"status":56,"phases":4395,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":24,"conditions":4396,"interventions":4397},[39],[20],[2581,1193],{"trials":4399,"activeCount":8},[],{"trials":4401,"activeCount":8},[],{"trials":4403,"activeCount":8},[],{"trials":4405,"activeCount":8},[],{"intervention":4407,"totalTrials":519,"cells":4408},"MSC2490484A",{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4421,"PHASE3":4423,"PHASE4":4425,"NA":4427},{"trials":4410,"activeCount":8},[],{"trials":4412,"activeCount":8},[4413],{"nctId":4414,"briefTitle":4415,"status":56,"phases":4416,"primaryCompletion":4417,"completion":4417,"start":3972,"enrollment":1482,"conditions":4418,"interventions":4420},"NCT02316197","Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia",[39],"2017-06-29",[3875,4419],"Chronic Lymphocytic Leukemia",[4407],{"trials":4422,"activeCount":8},[],{"trials":4424,"activeCount":8},[],{"trials":4426,"activeCount":8},[],{"trials":4428,"activeCount":8},[],{"intervention":3940,"totalTrials":519,"cells":4430},{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4439,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4432,"activeCount":8},[],{"trials":4434,"activeCount":8},[4435],{"nctId":3934,"briefTitle":3935,"status":56,"phases":4436,"primaryCompletion":2219,"completion":2219,"start":303,"enrollment":3937,"conditions":4437,"interventions":4438},[39],[17],[3927,3940],{"trials":4440,"activeCount":8},[],{"trials":4442,"activeCount":8},[],{"trials":4444,"activeCount":8},[],{"trials":4446,"activeCount":8},[],{"intervention":63,"totalTrials":519,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4450,"activeCount":8},[],{"trials":4452,"activeCount":8},[4453],{"nctId":54,"briefTitle":55,"status":56,"phases":4454,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":4455,"interventions":4456},[39],[20],[63,46,64],{"trials":4458,"activeCount":8},[],{"trials":4460,"activeCount":8},[],{"trials":4462,"activeCount":8},[],{"trials":4464,"activeCount":8},[],{"intervention":64,"totalTrials":519,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4468,"activeCount":8},[],{"trials":4470,"activeCount":8},[4471],{"nctId":54,"briefTitle":55,"status":56,"phases":4472,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":4473,"interventions":4474},[39],[20],[63,46,64],{"trials":4476,"activeCount":8},[],{"trials":4478,"activeCount":8},[],{"trials":4480,"activeCount":8},[],{"trials":4482,"activeCount":8},[],{"intervention":4484,"totalTrials":519,"cells":4485},"Test GXR",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4499,"PHASE3":4501,"PHASE4":4503,"NA":4505},{"trials":4487,"activeCount":8},[],{"trials":4489,"activeCount":8},[4490],{"nctId":4491,"briefTitle":4492,"status":56,"phases":4493,"primaryCompletion":4494,"completion":4494,"start":4495,"enrollment":4144,"conditions":4496,"interventions":4497},"NCT03566810","Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)",[39],"2018-11-28","2018-10-11",[20],[4484,4498],"Reference GXR",{"trials":4500,"activeCount":8},[],{"trials":4502,"activeCount":8},[],{"trials":4504,"activeCount":8},[],{"trials":4506,"activeCount":8},[],{"intervention":4498,"totalTrials":519,"cells":4508},{"EARLY_PHASE1":4509,"PHASE1":4511,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4510,"activeCount":8},[],{"trials":4512,"activeCount":8},[4513],{"nctId":4491,"briefTitle":4492,"status":56,"phases":4514,"primaryCompletion":4494,"completion":4494,"start":4495,"enrollment":4144,"conditions":4515,"interventions":4516},[39],[20],[4484,4498],{"trials":4518,"activeCount":8},[],{"trials":4520,"activeCount":8},[],{"trials":4522,"activeCount":8},[],{"trials":4524,"activeCount":8},[],{"intervention":4526,"totalTrials":519,"cells":4527},"EMD525797",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4539,"PHASE3":4541,"PHASE4":4543,"NA":4545},{"trials":4529,"activeCount":8},[],{"trials":4531,"activeCount":8},[4532],{"nctId":4533,"briefTitle":4534,"status":56,"phases":4535,"primaryCompletion":535,"completion":4536,"start":900,"enrollment":1058,"conditions":4537,"interventions":4538},"NCT01327313","A Study of EMD525797 in Solid Tumor Patients in Japan",[39],"2012-10",[2648],[4526,4526,4526,4526],{"trials":4540,"activeCount":8},[],{"trials":4542,"activeCount":8},[],{"trials":4544,"activeCount":8},[],{"trials":4546,"activeCount":8},[],{"intervention":4548,"totalTrials":519,"cells":4549},"MSB0010841",{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4561,"PHASE3":4563,"PHASE4":4565,"NA":4567},{"trials":4551,"activeCount":8},[],{"trials":4553,"activeCount":8},[4554],{"nctId":4555,"briefTitle":4556,"status":56,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":1439,"enrollment":604,"conditions":4559,"interventions":4560},"NCT02156466","Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A\u002FF Nanobody) in Psoriasis Subjects",[39],"2015-08",[272],[4548,4548,4548,4548],{"trials":4562,"activeCount":8},[],{"trials":4564,"activeCount":8},[],{"trials":4566,"activeCount":8},[],{"trials":4568,"activeCount":8},[],{"intervention":4570,"totalTrials":519,"cells":4571},"MSC2156119J",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4584,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4573,"activeCount":8},[],{"trials":4575,"activeCount":8},[4576],{"nctId":4577,"briefTitle":4578,"status":56,"phases":4579,"primaryCompletion":4580,"completion":3973,"start":4581,"enrollment":2588,"conditions":4582,"interventions":4583},"NCT01832506","A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors",[39],"2014-03-31","2013-04-30",[34],[4570],{"trials":4585,"activeCount":8},[],{"trials":4587,"activeCount":8},[],{"trials":4589,"activeCount":8},[],{"trials":4591,"activeCount":8},[],{"intervention":3977,"totalTrials":519,"cells":4593},{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4602,"PHASE3":4604,"PHASE4":4606,"NA":4608},{"trials":4595,"activeCount":8},[],{"trials":4597,"activeCount":8},[4598],{"nctId":3969,"briefTitle":3970,"status":56,"phases":4599,"primaryCompletion":3972,"completion":3972,"start":3973,"enrollment":3974,"conditions":4600,"interventions":4601},[39],[20],[3977,3962,3977,3977,3977,3977],{"trials":4603,"activeCount":8},[],{"trials":4605,"activeCount":8},[],{"trials":4607,"activeCount":8},[],{"trials":4609,"activeCount":8},[],{"intervention":4611,"totalTrials":519,"cells":4612},"L-PZQ ODT",{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4626,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4614,"activeCount":8},[],{"trials":4616,"activeCount":8},[4617],{"nctId":4618,"briefTitle":4619,"status":56,"phases":4620,"primaryCompletion":3469,"completion":3469,"start":3468,"enrollment":4621,"conditions":4622,"interventions":4623},"NCT02315352","Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years",[39],48,[20],[4611,4624,4611,4624,4625],"Rac-PZQ ODT","Cesol®",{"trials":4627,"activeCount":8},[],{"trials":4629,"activeCount":8},[],{"trials":4631,"activeCount":8},[],{"trials":4633,"activeCount":8},[],{"intervention":4624,"totalTrials":519,"cells":4635},{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4644,"PHASE3":4646,"PHASE4":4648,"NA":4650},{"trials":4637,"activeCount":8},[],{"trials":4639,"activeCount":8},[4640],{"nctId":4618,"briefTitle":4619,"status":56,"phases":4641,"primaryCompletion":3469,"completion":3469,"start":3468,"enrollment":4621,"conditions":4642,"interventions":4643},[39],[20],[4611,4624,4611,4624,4625],{"trials":4645,"activeCount":8},[],{"trials":4647,"activeCount":8},[],{"trials":4649,"activeCount":8},[],{"trials":4651,"activeCount":8},[],{"intervention":4625,"totalTrials":519,"cells":4653},{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4662,"PHASE3":4664,"PHASE4":4666,"NA":4668},{"trials":4655,"activeCount":8},[],{"trials":4657,"activeCount":8},[4658],{"nctId":4618,"briefTitle":4619,"status":56,"phases":4659,"primaryCompletion":3469,"completion":3469,"start":3468,"enrollment":4621,"conditions":4660,"interventions":4661},[39],[20],[4611,4624,4611,4624,4625],{"trials":4663,"activeCount":8},[],{"trials":4665,"activeCount":8},[],{"trials":4667,"activeCount":8},[],{"trials":4669,"activeCount":8},[],{"intervention":2591,"totalTrials":519,"cells":4671},{"EARLY_PHASE1":4672,"PHASE1":4674,"PHASE2":4680,"PHASE3":4682,"PHASE4":4684,"NA":4686},{"trials":4673,"activeCount":8},[],{"trials":4675,"activeCount":8},[4676],{"nctId":2583,"briefTitle":2584,"status":56,"phases":4677,"primaryCompletion":2586,"completion":2586,"start":2587,"enrollment":2588,"conditions":4678,"interventions":4679},[39],[20],[1193,2591],{"trials":4681,"activeCount":8},[],{"trials":4683,"activeCount":8},[],{"trials":4685,"activeCount":8},[],{"trials":4687,"activeCount":8},[],{"intervention":4689,"totalTrials":519,"cells":4690},"EMD 72000 (matuzumab) + ECX",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4692,"activeCount":8},[],{"trials":4694,"activeCount":8},[4695],{"nctId":4696,"briefTitle":4697,"status":56,"phases":4698,"primaryCompletion":4699,"completion":1331,"start":4700,"enrollment":3873,"conditions":4701,"interventions":4702},"NCT00113581","Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer",[39],"2006-05","2002-10",[1205,1206],[4689],{"trials":4704,"activeCount":8},[],{"trials":4706,"activeCount":8},[],{"trials":4708,"activeCount":8},[],{"trials":4710,"activeCount":8},[],{"intervention":4712,"totalTrials":519,"cells":4713},"MSC1936369B",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4728,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4715,"activeCount":8},[],{"trials":4717,"activeCount":8},[4718],{"nctId":4719,"briefTitle":4720,"status":56,"phases":4721,"primaryCompletion":4722,"completion":187,"start":4723,"enrollment":4724,"conditions":4725,"interventions":4727},"NCT00982865","Trial of MSC1936369B in Subjects With Solid Tumors",[39],"2013-03-31","2007-12-31",182,[34,4726],"Cancer",[4712,4712,4712,4712],{"trials":4729,"activeCount":8},[],{"trials":4731,"activeCount":8},[],{"trials":4733,"activeCount":8},[],{"trials":4735,"activeCount":8},[],{"intervention":4737,"totalTrials":519,"cells":4738},"M5049",{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4752,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4740,"activeCount":8},[],{"trials":4742,"activeCount":8},[4743],{"nctId":4744,"briefTitle":4745,"status":56,"phases":4746,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":4749,"conditions":4750,"interventions":4751},"NCT03676322","Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants",[39],"2019-07-26","2018-09-20",96,[20],[4737],{"trials":4753,"activeCount":8},[],{"trials":4755,"activeCount":8},[],{"trials":4757,"activeCount":8},[],{"trials":4759,"activeCount":8},[],{"intervention":4761,"totalTrials":519,"cells":4762},"Tepotinib test",{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4776,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4764,"activeCount":8},[],{"trials":4766,"activeCount":8},[4767],{"nctId":4768,"briefTitle":4769,"status":56,"phases":4770,"primaryCompletion":3193,"completion":3193,"start":4771,"enrollment":4772,"conditions":4773,"interventions":4774},"NCT03021642","Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers",[39],"2016-01-31",24,[20],[4761,4775,4775,4761],"Tepotinib reference",{"trials":4777,"activeCount":8},[],{"trials":4779,"activeCount":8},[],{"trials":4781,"activeCount":8},[],{"trials":4783,"activeCount":8},[],{"intervention":4775,"totalTrials":519,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4794,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4787,"activeCount":8},[],{"trials":4789,"activeCount":8},[4790],{"nctId":4768,"briefTitle":4769,"status":56,"phases":4791,"primaryCompletion":3193,"completion":3193,"start":4771,"enrollment":4772,"conditions":4792,"interventions":4793},[39],[20],[4761,4775,4775,4761],{"trials":4795,"activeCount":8},[],{"trials":4797,"activeCount":8},[],{"trials":4799,"activeCount":8},[],{"trials":4801,"activeCount":8},[],{"intervention":4803,"totalTrials":519,"cells":4804},"Glucophage XR",{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4817,"PHASE3":4819,"PHASE4":4821,"NA":4823},{"trials":4806,"activeCount":8},[],{"trials":4808,"activeCount":8},[4809],{"nctId":4810,"briefTitle":4811,"status":56,"phases":4812,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":4621,"conditions":4815,"interventions":4816},"NCT03583385","Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study",[39],"2018-10-05","2018-08-16",[20],[4803,4803],{"trials":4818,"activeCount":8},[],{"trials":4820,"activeCount":8},[],{"trials":4822,"activeCount":8},[],{"trials":4824,"activeCount":8},[],{"intervention":4826,"totalTrials":519,"cells":4827},"Tepotinib TF2",{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4840,"PHASE3":4842,"PHASE4":4844,"NA":4846},{"trials":4829,"activeCount":8},[],{"trials":4831,"activeCount":8},[4832],{"nctId":4833,"briefTitle":4834,"status":56,"phases":4835,"primaryCompletion":4836,"completion":4836,"start":4134,"enrollment":2609,"conditions":4837,"interventions":4838},"NCT03629223","Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib",[39],"2019-01-25",[20],[4826,4839],"Tepotinib TF3",{"trials":4841,"activeCount":8},[],{"trials":4843,"activeCount":8},[],{"trials":4845,"activeCount":8},[],{"trials":4847,"activeCount":8},[],{"intervention":4839,"totalTrials":519,"cells":4849},{"EARLY_PHASE1":4850,"PHASE1":4852,"PHASE2":4858,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4851,"activeCount":8},[],{"trials":4853,"activeCount":8},[4854],{"nctId":4833,"briefTitle":4834,"status":56,"phases":4855,"primaryCompletion":4836,"completion":4836,"start":4134,"enrollment":2609,"conditions":4856,"interventions":4857},[39],[20],[4826,4839],{"trials":4859,"activeCount":8},[],{"trials":4861,"activeCount":8},[],{"trials":4863,"activeCount":8},[],{"trials":4865,"activeCount":8},[],{"intervention":4867,"totalTrials":519,"cells":4868},"Berzosertib",{"EARLY_PHASE1":4869,"PHASE1":4871,"PHASE2":4881,"PHASE3":4883,"PHASE4":4885,"NA":4887},{"trials":4870,"activeCount":8},[],{"trials":4872,"activeCount":8},[4873],{"nctId":4874,"briefTitle":4875,"status":56,"phases":4876,"primaryCompletion":4877,"completion":4877,"start":4357,"enrollment":519,"conditions":4878,"interventions":4880},"NCT03309150","ATRi Transition Rollover Study",[39],"2024-01-26",[4879],"Advanced Stage Solid Tumors",[4867],{"trials":4882,"activeCount":8},[],{"trials":4884,"activeCount":8},[],{"trials":4886,"activeCount":8},[],{"trials":4888,"activeCount":8},[],{"intervention":2600,"totalTrials":519,"cells":4890},{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4899,"PHASE3":4901,"PHASE4":4903,"NA":4905},{"trials":4892,"activeCount":8},[],{"trials":4894,"activeCount":8},[4895],{"nctId":2593,"briefTitle":2594,"status":56,"phases":4896,"primaryCompletion":2596,"completion":1175,"start":2597,"enrollment":2588,"conditions":4897,"interventions":4898},[39],[20],[2600,1193],{"trials":4900,"activeCount":8},[],{"trials":4902,"activeCount":8},[],{"trials":4904,"activeCount":8},[],{"trials":4906,"activeCount":8},[],{"intervention":4908,"totalTrials":519,"cells":4909},"M5717",{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4928},{"trials":4911,"activeCount":8},[],{"trials":4913,"activeCount":8},[4914],{"nctId":4915,"briefTitle":4916,"status":56,"phases":4917,"primaryCompletion":4918,"completion":4918,"start":4919,"enrollment":1189,"conditions":4920,"interventions":4921},"NCT03261401","First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants",[39],"2019-06-14","2017-09-15",[20],[4908,4908],{"trials":4923,"activeCount":8},[],{"trials":4925,"activeCount":8},[],{"trials":4927,"activeCount":8},[],{"trials":4929,"activeCount":8},[],{"intervention":4049,"totalTrials":519,"cells":4931},{"EARLY_PHASE1":4932,"PHASE1":4934,"PHASE2":4940,"PHASE3":4942,"PHASE4":4944,"NA":4946},{"trials":4933,"activeCount":8},[],{"trials":4935,"activeCount":8},[4936],{"nctId":4042,"briefTitle":4043,"status":56,"phases":4937,"primaryCompletion":4045,"completion":4045,"start":4046,"enrollment":1217,"conditions":4938,"interventions":4939},[39],[20],[4027,4049,4050],{"trials":4941,"activeCount":8},[],{"trials":4943,"activeCount":8},[],{"trials":4945,"activeCount":8},[],{"trials":4947,"activeCount":8},[],{"intervention":4050,"totalTrials":519,"cells":4949},{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4958,"PHASE3":4960,"PHASE4":4962,"NA":4964},{"trials":4951,"activeCount":8},[],{"trials":4953,"activeCount":8},[4954],{"nctId":4042,"briefTitle":4043,"status":56,"phases":4955,"primaryCompletion":4045,"completion":4045,"start":4046,"enrollment":1217,"conditions":4956,"interventions":4957},[39],[20],[4027,4049,4050],{"trials":4959,"activeCount":8},[],{"trials":4961,"activeCount":8},[],{"trials":4963,"activeCount":8},[],{"trials":4965,"activeCount":8},[],{"intervention":4967,"totalTrials":519,"cells":4968},"MSB0011359C",{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":4981,"PHASE3":4983,"PHASE4":4985,"NA":4987},{"trials":4970,"activeCount":8},[],{"trials":4972,"activeCount":8},[4973],{"nctId":4974,"briefTitle":4975,"status":56,"phases":4976,"primaryCompletion":474,"completion":474,"start":4977,"enrollment":4978,"conditions":4979,"interventions":4980},"NCT02699515","MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors",[39],"2016-03-11",114,[34],[4967],{"trials":4982,"activeCount":8},[],{"trials":4984,"activeCount":8},[],{"trials":4986,"activeCount":8},[],{"trials":4988,"activeCount":8},[],{"intervention":4990,"totalTrials":519,"cells":4991},"[14C] TH-302",{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":5006,"PHASE3":5008,"PHASE4":5010,"NA":5012},{"trials":4993,"activeCount":8},[],{"trials":4995,"activeCount":8},[4996],{"nctId":4997,"briefTitle":4998,"status":56,"phases":4999,"primaryCompletion":5000,"completion":720,"start":5001,"enrollment":5002,"conditions":5003,"interventions":5004},"NCT02076230","A Phase 1 TH-302 Mass Balance Trial",[39],"2014-09","2014-02",10,[2648],[4990,4990,5005],"Unlabeled TH-302",{"trials":5007,"activeCount":8},[],{"trials":5009,"activeCount":8},[],{"trials":5011,"activeCount":8},[],{"trials":5013,"activeCount":8},[],{"intervention":5005,"totalTrials":519,"cells":5015},{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5024,"PHASE3":5026,"PHASE4":5028,"NA":5030},{"trials":5017,"activeCount":8},[],{"trials":5019,"activeCount":8},[5020],{"nctId":4997,"briefTitle":4998,"status":56,"phases":5021,"primaryCompletion":5000,"completion":720,"start":5001,"enrollment":5002,"conditions":5022,"interventions":5023},[39],[2648],[4990,4990,5005],{"trials":5025,"activeCount":8},[],{"trials":5027,"activeCount":8},[],{"trials":5029,"activeCount":8},[],{"trials":5031,"activeCount":8},[],{"intervention":3952,"totalTrials":519,"cells":5033},{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5042,"PHASE3":5044,"PHASE4":5046,"NA":5048},{"trials":5035,"activeCount":8},[],{"trials":5037,"activeCount":8},[5038],{"nctId":3942,"briefTitle":3943,"status":56,"phases":5039,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":3948,"conditions":5040,"interventions":5041},[39],[3950],[3927,3952],{"trials":5043,"activeCount":8},[],{"trials":5045,"activeCount":8},[],{"trials":5047,"activeCount":8},[],{"trials":5049,"activeCount":8},[],{"intervention":5051,"totalTrials":519,"cells":5052},"Avelumab 3 mg\u002Fkg Q2W",{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5070,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5054,"activeCount":8},[],{"trials":5056,"activeCount":8},[5057],{"nctId":5058,"briefTitle":5059,"status":56,"phases":5060,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":4772,"conditions":5064,"interventions":5066},"NCT03523390","Phase I\u002FIb Multiple Ascending Dose Study in China",[39],"2019-07-29","2021-02-08","2018-04-24",[5065],"Metastatic Solid Tumors",[5051,5067,5068,5069],"Avelumab 10 mg\u002Fkg Q2W","Avelumab 20 mg\u002Fkg Q2W","Avelumab 10 mg\u002Fkg QW",{"trials":5071,"activeCount":8},[],{"trials":5073,"activeCount":8},[],{"trials":5075,"activeCount":8},[],{"trials":5077,"activeCount":8},[],{"intervention":5067,"totalTrials":519,"cells":5079},{"EARLY_PHASE1":5080,"PHASE1":5082,"PHASE2":5088,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5081,"activeCount":8},[],{"trials":5083,"activeCount":8},[5084],{"nctId":5058,"briefTitle":5059,"status":56,"phases":5085,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":4772,"conditions":5086,"interventions":5087},[39],[5065],[5051,5067,5068,5069],{"trials":5089,"activeCount":8},[],{"trials":5091,"activeCount":8},[],{"trials":5093,"activeCount":8},[],{"trials":5095,"activeCount":8},[],{"intervention":5068,"totalTrials":519,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5106,"PHASE3":5108,"PHASE4":5110,"NA":5112},{"trials":5099,"activeCount":8},[],{"trials":5101,"activeCount":8},[5102],{"nctId":5058,"briefTitle":5059,"status":56,"phases":5103,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":4772,"conditions":5104,"interventions":5105},[39],[5065],[5051,5067,5068,5069],{"trials":5107,"activeCount":8},[],{"trials":5109,"activeCount":8},[],{"trials":5111,"activeCount":8},[],{"trials":5113,"activeCount":8},[],{"intervention":5069,"totalTrials":519,"cells":5115},{"EARLY_PHASE1":5116,"PHASE1":5118,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5117,"activeCount":8},[],{"trials":5119,"activeCount":8},[5120],{"nctId":5058,"briefTitle":5059,"status":56,"phases":5121,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":4772,"conditions":5122,"interventions":5123},[39],[5065],[5051,5067,5068,5069],{"trials":5125,"activeCount":8},[],{"trials":5127,"activeCount":8},[],{"trials":5129,"activeCount":8},[],{"trials":5131,"activeCount":8},[],{"intervention":5133,"totalTrials":519,"cells":5134},"Avelumab 3 mg\u002Fkg",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5151,"PHASE3":5153,"PHASE4":5155,"NA":5157},{"trials":5136,"activeCount":8},[],{"trials":5138,"activeCount":8},[5139],{"nctId":5140,"briefTitle":5141,"status":56,"phases":5142,"primaryCompletion":5143,"completion":5144,"start":5145,"enrollment":5146,"conditions":5147,"interventions":5148},"NCT01943461","Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)",[39],"2015-01-07","2019-09-25","2013-09-02",57,[34],[5133,5149,5150],"Avelumab 10 mg\u002Fkg","Avelumab 20 mg\u002Fkg",{"trials":5152,"activeCount":8},[],{"trials":5154,"activeCount":8},[],{"trials":5156,"activeCount":8},[],{"trials":5158,"activeCount":8},[],{"intervention":5149,"totalTrials":519,"cells":5160},{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5175},{"trials":5162,"activeCount":8},[],{"trials":5164,"activeCount":8},[5165],{"nctId":5140,"briefTitle":5141,"status":56,"phases":5166,"primaryCompletion":5143,"completion":5144,"start":5145,"enrollment":5146,"conditions":5167,"interventions":5168},[39],[34],[5133,5149,5150],{"trials":5170,"activeCount":8},[],{"trials":5172,"activeCount":8},[],{"trials":5174,"activeCount":8},[],{"trials":5176,"activeCount":8},[],{"intervention":5150,"totalTrials":519,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5187,"PHASE3":5189,"PHASE4":5191,"NA":5193},{"trials":5180,"activeCount":8},[],{"trials":5182,"activeCount":8},[5183],{"nctId":5140,"briefTitle":5141,"status":56,"phases":5184,"primaryCompletion":5143,"completion":5144,"start":5145,"enrollment":5146,"conditions":5185,"interventions":5186},[39],[34],[5133,5149,5150],{"trials":5188,"activeCount":8},[],{"trials":5190,"activeCount":8},[],{"trials":5192,"activeCount":8},[],{"trials":5194,"activeCount":8},[],{"intervention":5196,"totalTrials":519,"cells":5197},"AS703569\u002Fgemcitabine",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5208,"PHASE3":5210,"PHASE4":5212,"NA":5214},{"trials":5199,"activeCount":8},[],{"trials":5201,"activeCount":8},[5202],{"nctId":5203,"briefTitle":5204,"status":56,"phases":5205,"primaryCompletion":93,"completion":1147,"start":1148,"enrollment":2609,"conditions":5206,"interventions":5207},"NCT01097512","AS703569 and Gemcitabine Combination in Advanced Malignancies",[39],[2649],[5196,5196],{"trials":5209,"activeCount":8},[],{"trials":5211,"activeCount":8},[],{"trials":5213,"activeCount":8},[],{"trials":5215,"activeCount":8},[],{"intervention":5217,"totalTrials":519,"cells":5218},"EMD 1201081 + 5-FU + Cisplatin + Cetuximab",{"EARLY_PHASE1":5219,"PHASE1":5221,"PHASE2":5230,"PHASE3":5232,"PHASE4":5234,"NA":5236},{"trials":5220,"activeCount":8},[],{"trials":5222,"activeCount":8},[5223],{"nctId":5224,"briefTitle":5225,"status":130,"phases":5226,"primaryCompletion":536,"start":1057,"enrollment":5227,"conditions":5228,"interventions":5229},"NCT01360827","EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent \u002F Metastatic Squamous Cell Carcinoma of the Head and Neck",[39],13,[1229],[5217,5217],{"trials":5231,"activeCount":8},[],{"trials":5233,"activeCount":8},[],{"trials":5235,"activeCount":8},[],{"trials":5237,"activeCount":8},[],{"intervention":2651,"totalTrials":519,"cells":5239},{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5241,"activeCount":8},[],{"trials":5243,"activeCount":8},[5244],{"nctId":2643,"briefTitle":2644,"status":56,"phases":5245,"primaryCompletion":404,"completion":1762,"start":2646,"enrollment":24,"conditions":5246,"interventions":5247},[39],[2648,2649],[2651,1166],{"trials":5249,"activeCount":8},[],{"trials":5251,"activeCount":8},[],{"trials":5253,"activeCount":8},[],{"trials":5255,"activeCount":8},[],{"intervention":3985,"totalTrials":519,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5266,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5259,"activeCount":8},[],{"trials":5261,"activeCount":8},[5262],{"nctId":3979,"briefTitle":3980,"status":56,"phases":5263,"primaryCompletion":3982,"completion":1440,"start":3982,"enrollment":60,"conditions":5264,"interventions":5265},[39],[20],[3985,3962,3986,3986,3986,3962],{"trials":5267,"activeCount":8},[],{"trials":5269,"activeCount":8},[],{"trials":5271,"activeCount":8},[],{"trials":5273,"activeCount":8},[],{"intervention":3986,"totalTrials":519,"cells":5275},{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5284,"PHASE3":5286,"PHASE4":5288,"NA":5290},{"trials":5277,"activeCount":8},[],{"trials":5279,"activeCount":8},[5280],{"nctId":3979,"briefTitle":3980,"status":56,"phases":5281,"primaryCompletion":3982,"completion":1440,"start":3982,"enrollment":60,"conditions":5282,"interventions":5283},[39],[20],[3985,3962,3986,3986,3986,3962],{"trials":5285,"activeCount":8},[],{"trials":5287,"activeCount":8},[],{"trials":5289,"activeCount":8},[],{"trials":5291,"activeCount":8},[],{"intervention":5293,"totalTrials":519,"cells":5294},"Cisticid",{"EARLY_PHASE1":5295,"PHASE1":5297,"PHASE2":5309,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5296,"activeCount":8},[],{"trials":5298,"activeCount":8},[5299],{"nctId":5300,"briefTitle":5301,"status":56,"phases":5302,"primaryCompletion":5303,"completion":5303,"start":5304,"enrollment":5305,"conditions":5306,"interventions":5307},"NCT03437447","Praziquantel Bioequivalence Study",[39],"2018-07-06","2018-06-18",60,[20],[5293,5308],"Biltricide",{"trials":5310,"activeCount":8},[],{"trials":5312,"activeCount":8},[],{"trials":5314,"activeCount":8},[],{"trials":5316,"activeCount":8},[],{"intervention":5308,"totalTrials":519,"cells":5318},{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5327,"PHASE3":5329,"PHASE4":5331,"NA":5333},{"trials":5320,"activeCount":8},[],{"trials":5322,"activeCount":8},[5323],{"nctId":5300,"briefTitle":5301,"status":56,"phases":5324,"primaryCompletion":5303,"completion":5303,"start":5304,"enrollment":5305,"conditions":5325,"interventions":5326},[39],[20],[5293,5308],{"trials":5328,"activeCount":8},[],{"trials":5330,"activeCount":8},[],{"trials":5332,"activeCount":8},[],{"trials":5334,"activeCount":8},[],{"intervention":1141,"totalTrials":24,"cells":5336},{"EARLY_PHASE1":5337,"PHASE1":5339,"PHASE2":5341,"PHASE3":5389,"PHASE4":5411,"NA":5413},{"trials":5338,"activeCount":8},[],{"trials":5340,"activeCount":8},[],{"trials":5342,"activeCount":8},[5343,5347,5351,5355,5362,5369,5373,5377,5381,5385],{"nctId":1131,"briefTitle":1132,"status":56,"phases":5344,"primaryCompletion":499,"completion":721,"start":1134,"enrollment":1135,"conditions":5345,"interventions":5346},[39,40],[1137],[1139,1140,1141,1142,1122],{"nctId":1156,"briefTitle":1157,"status":56,"phases":5348,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":1161,"conditions":5349,"interventions":5350},[40],[1163],[1165,1165,1141,1122,1122,1166,1167,1165,1165,1141,1168],{"nctId":1170,"briefTitle":1171,"status":56,"phases":5352,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":5353,"interventions":5354},[40],[1178],[1180,1141,1166,1122,1181],{"nctId":5356,"briefTitle":5357,"status":56,"phases":5358,"primaryCompletion":813,"completion":813,"start":85,"enrollment":1227,"conditions":5359,"interventions":5361},"NCT01450319","Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype",[40],[5360],"Colorectal Neoplasms",[1141],{"nctId":5363,"briefTitle":5364,"status":56,"phases":5365,"primaryCompletion":4006,"completion":4006,"start":746,"enrollment":1058,"conditions":5366,"interventions":5368},"NCT00865098","Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[40],[5367],"Carcinoma of the Head and Neck",[1141],{"nctId":1380,"briefTitle":1381,"status":56,"phases":5370,"primaryCompletion":745,"start":220,"enrollment":1383,"conditions":5371,"interventions":5372},[40],[1229],[1141,1386,1231],{"nctId":1692,"briefTitle":1693,"status":56,"phases":5374,"primaryCompletion":112,"completion":112,"start":1160,"enrollment":1695,"conditions":5375,"interventions":5376},[39,40],[1697],[1141,1683,1699],{"nctId":3509,"briefTitle":3510,"status":56,"phases":5378,"primaryCompletion":3468,"completion":3468,"start":857,"enrollment":1161,"conditions":5379,"interventions":5380},[39,40],[1697],[3500,3514,3515,3516,1141,3517],{"nctId":1212,"briefTitle":1213,"status":56,"phases":5382,"primaryCompletion":856,"completion":1215,"start":1216,"enrollment":1217,"conditions":5383,"interventions":5384},[40],[1206],[1141,1122,1220],{"nctId":1747,"briefTitle":1748,"status":56,"phases":5386,"primaryCompletion":234,"completion":104,"start":1750,"enrollment":1751,"conditions":5387,"interventions":5388},[40],[1753,1754],[1141,1738],{"trials":5390,"activeCount":8},[5391,5395,5399,5403,5407],{"nctId":1703,"briefTitle":1704,"status":56,"phases":5392,"primaryCompletion":1706,"completion":745,"start":168,"enrollment":1707,"conditions":5393,"interventions":5394},[41],[1709],[1141,1683],{"nctId":1224,"briefTitle":1225,"status":56,"phases":5396,"primaryCompletion":900,"completion":371,"start":76,"enrollment":1227,"conditions":5397,"interventions":5398},[41],[1229],[1141,1122,1231],{"nctId":1233,"briefTitle":1234,"status":56,"phases":5400,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":5401,"interventions":5402},[41],[1206],[1141,1210,1122],{"nctId":1394,"briefTitle":1395,"status":56,"phases":5404,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":5405,"interventions":5406},[41],[1402],[1141,1386,1142],{"nctId":1759,"briefTitle":1760,"status":56,"phases":5408,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":5409,"interventions":5410},[41],[1697],[1141,1738,1768,1769],{"trials":5412,"activeCount":8},[],{"trials":5414,"activeCount":8},[5415,5422,5430,5440,5448],{"nctId":5416,"briefTitle":5417,"status":768,"phases":5418,"primaryCompletion":746,"start":746,"enrollment":8,"conditions":5419,"interventions":5421},"NCT01075841","A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic\u002FRecurrent Squamous Cell Cancer of the Head and Neck",[],[5420],"Neoplasms, Squamous Cell",[1141],{"nctId":5423,"briefTitle":5424,"status":130,"phases":5425,"primaryCompletion":85,"completion":4070,"start":232,"enrollment":5426,"conditions":5427,"interventions":5429},"NCT01074333","An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment",[],146,[5428],"Colorectal Neoplasm",[1141],{"nctId":5431,"briefTitle":5432,"status":130,"phases":5433,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":966,"conditions":5437,"interventions":5439},"NCT01142869","An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck",[],"2013-07-31","2014-08-05","2009-12-31",[5438],"Carcinoma, Squamous Cell",[1141],{"nctId":5441,"briefTitle":5442,"status":130,"phases":5443,"primaryCompletion":5434,"completion":5435,"start":5444,"enrollment":5445,"conditions":5446,"interventions":5447},"NCT01134666","An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI \u002F FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer",[],"2009-11-30",165,[5360],[1141],{"nctId":5449,"briefTitle":5450,"status":56,"phases":5451,"primaryCompletion":5452,"completion":5452,"start":746,"enrollment":5453,"conditions":5454,"interventions":5455},"NCT01075828","Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and\u002For Metastatic Squamous Cell Cancer of the Head and Neck in Korea",[],"2014-07",221,[2179],[1141],{"intervention":1351,"totalTrials":3683,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5464,"PHASE4":5488,"NA":5497},{"trials":5459,"activeCount":8},[],{"trials":5461,"activeCount":8},[],{"trials":5463,"activeCount":8},[],{"trials":5465,"activeCount":8},[5466,5470,5474,5478],{"nctId":1342,"briefTitle":1343,"status":56,"phases":5467,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":123,"conditions":5468,"interventions":5469},[41],[1348,1349],[1351,409,409,1306],{"nctId":401,"briefTitle":402,"status":56,"phases":5471,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":5472,"interventions":5473},[41],[14],[409,410,390],{"nctId":1353,"briefTitle":1354,"status":130,"phases":5475,"primaryCompletion":1356,"completion":1356,"start":382,"enrollment":1357,"conditions":5476,"interventions":5477},[41],[14,1359,1360],[410,1362,1306],{"nctId":5479,"briefTitle":5480,"status":56,"phases":5481,"primaryCompletion":5482,"completion":5482,"start":5483,"enrollment":5484,"conditions":5485,"interventions":5487},"NCT01183143","Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization",[41],"2006-03-02","2004-05-11",215,[14,32,5486],"In-Vitro Fertilization",[410],{"trials":5489,"activeCount":8},[5490],{"nctId":5491,"briefTitle":5492,"status":130,"phases":5493,"primaryCompletion":1919,"completion":2088,"start":1159,"enrollment":4772,"conditions":5494,"interventions":5496},"NCT01871532","Low-dose Gonal-f® in Ovulation Induction",[42],[14,5495],"Monofollicular Development",[1351],{"trials":5498,"activeCount":8},[5499,5511],{"nctId":5500,"briefTitle":5501,"status":56,"phases":5502,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":5506,"conditions":5507,"interventions":5509},"NCT02607293","A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation",[],"2017-03-16","2017-06-28","2015-12-31",1064,[5508],"Polycystic Ovary Syndrome",[1351,5510,1510],"Long GnRH agonist",{"nctId":5512,"briefTitle":5513,"status":56,"phases":5514,"primaryCompletion":1238,"completion":5515,"start":5516,"enrollment":313,"conditions":5517,"interventions":5518},"NCT01115725","A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)",[],"2008-07","2005-11",[14],[1351],{"intervention":1265,"totalTrials":3683,"cells":5520},{"EARLY_PHASE1":5521,"PHASE1":5523,"PHASE2":5525,"PHASE3":5547,"PHASE4":5553,"NA":5555},{"trials":5522,"activeCount":8},[],{"trials":5524,"activeCount":8},[],{"trials":5526,"activeCount":8},[5527,5531,5535,5539,5543],{"nctId":1256,"briefTitle":1257,"status":56,"phases":5528,"primaryCompletion":1259,"completion":535,"start":1260,"enrollment":1261,"conditions":5529,"interventions":5530},[40],[1263,1163],[1265,1247],{"nctId":1267,"briefTitle":1268,"status":56,"phases":5532,"primaryCompletion":1270,"completion":1271,"start":603,"enrollment":1272,"conditions":5533,"interventions":5534},[40],[1163,1263],[1265,1247],{"nctId":2764,"briefTitle":2765,"status":56,"phases":5536,"primaryCompletion":2767,"completion":2767,"start":103,"enrollment":2768,"conditions":5537,"interventions":5538},[40],[2770],[1265,2772],{"nctId":1276,"briefTitle":1277,"status":56,"phases":5540,"primaryCompletion":498,"completion":1279,"start":94,"enrollment":1280,"conditions":5541,"interventions":5542},[39,40],[1191],[1265,1247],{"nctId":1284,"briefTitle":1285,"status":56,"phases":5544,"primaryCompletion":1147,"completion":1236,"start":303,"enrollment":337,"conditions":5545,"interventions":5546},[40],[1288],[1265,1265,1247,1290],{"trials":5548,"activeCount":8},[5549],{"nctId":1294,"briefTitle":1295,"status":130,"phases":5550,"primaryCompletion":1279,"completion":1279,"start":76,"enrollment":1297,"conditions":5551,"interventions":5552},[41],[1299],[1265,1247],{"trials":5554,"activeCount":8},[],{"trials":5556,"activeCount":8},[5557],{"nctId":5558,"briefTitle":5559,"status":130,"phases":5560,"primaryCompletion":5561,"completion":4558,"start":4070,"enrollment":1058,"conditions":5562,"interventions":5563},"NCT01423760","Common Safety Follow-up Trial of Tecemotide (L-BLP25)",[43],"2015-07",[1299,1288],[1265],{"intervention":5565,"totalTrials":279,"cells":5566},"Interferon beta-1a",{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5571,"PHASE3":5582,"PHASE4":5584,"NA":5602},{"trials":5568,"activeCount":8},[],{"trials":5570,"activeCount":8},[],{"trials":5572,"activeCount":8},[5573],{"nctId":5574,"briefTitle":5575,"status":56,"phases":5576,"primaryCompletion":5577,"completion":5577,"start":5578,"enrollment":9,"conditions":5579,"interventions":5581},"NCT01075763","A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease",[40],"2008-05","2004-11",[5580],"Alzheimer's Disease",[5565],{"trials":5583,"activeCount":8},[],{"trials":5585,"activeCount":8},[5586,5595],{"nctId":5587,"briefTitle":5588,"status":56,"phases":5589,"primaryCompletion":93,"completion":93,"start":5590,"enrollment":5591,"conditions":5592,"interventions":5594},"NCT01201343","Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients",[42],"2005-01",79,[5593],"Multiple Sclerosis, Relapsing, Remitting",[5565],{"nctId":5596,"briefTitle":5597,"status":56,"phases":5598,"primaryCompletion":76,"completion":579,"start":256,"enrollment":5599,"conditions":5600,"interventions":5601},"NCT01142466","A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone",[42],30,[26],[5565],{"trials":5603,"activeCount":8},[5604,5611,5618],{"nctId":5605,"briefTitle":5606,"status":56,"phases":5607,"primaryCompletion":121,"completion":121,"start":579,"enrollment":5608,"conditions":5609,"interventions":5610},"NCT01101776","Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.",[],49,[17],[5565],{"nctId":5612,"briefTitle":5613,"status":56,"phases":5614,"primaryCompletion":5515,"completion":5515,"start":5590,"enrollment":5615,"conditions":5616,"interventions":5617},"NCT01142492","A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)",[],403,[3472],[5565],{"nctId":5619,"briefTitle":5620,"status":56,"phases":5621,"primaryCompletion":5516,"completion":5516,"start":5622,"enrollment":5623,"conditions":5624,"interventions":5625},"NCT01142557","An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis",[],"2004-06",522,[17],[5565],{"intervention":5627,"totalTrials":279,"cells":5628},"Rebif",{"EARLY_PHASE1":5629,"PHASE1":5631,"PHASE2":5633,"PHASE3":5643,"PHASE4":5645,"NA":5655},{"trials":5630,"activeCount":8},[],{"trials":5632,"activeCount":8},[],{"trials":5634,"activeCount":8},[5635],{"nctId":5636,"briefTitle":5637,"status":56,"phases":5638,"primaryCompletion":1440,"completion":811,"start":5639,"enrollment":5640,"conditions":5641,"interventions":5642},"NCT01198132","A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly",[40],"2009-11",129,[17],[5627],{"trials":5644,"activeCount":8},[],{"trials":5646,"activeCount":8},[5647],{"nctId":5648,"briefTitle":5649,"status":56,"phases":5650,"primaryCompletion":5651,"completion":5651,"start":3972,"enrollment":5652,"conditions":5653,"interventions":5654},"NCT02254304","Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™",[42],"2016-08-20",106,[2024,159],[5627],{"trials":5656,"activeCount":8},[5657,5665,5671,5678],{"nctId":5658,"briefTitle":5659,"status":130,"phases":5660,"primaryCompletion":5661,"completion":5661,"start":5662,"enrollment":287,"conditions":5663,"interventions":5664},"NCT02949908","MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)",[],"2017-08-25","2017-02-09",[17],[5627],{"nctId":5666,"briefTitle":5667,"status":56,"phases":5668,"primaryCompletion":721,"completion":721,"start":278,"enrollment":2136,"conditions":5669,"interventions":5670},"NCT01075880","Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®",[],[26],[5627],{"nctId":5672,"briefTitle":5673,"status":56,"phases":5674,"primaryCompletion":5452,"completion":5452,"start":4070,"enrollment":5675,"conditions":5676,"interventions":5677},"NCT01601119","Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",[],545,[2024],[5627],{"nctId":5679,"briefTitle":5680,"status":56,"phases":5681,"primaryCompletion":5682,"completion":5682,"start":5683,"enrollment":5684,"conditions":5685,"interventions":5686},"NCT02921035","Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)",[],"2020-07-27","2016-06-30",594,[3950],[5627],{"intervention":1467,"totalTrials":141,"cells":5688},{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5699,"PHASE4":5709,"NA":5711},{"trials":5690,"activeCount":8},[],{"trials":5692,"activeCount":8},[],{"trials":5694,"activeCount":8},[5695],{"nctId":1459,"briefTitle":1460,"status":56,"phases":5696,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":5697,"interventions":5698},[40],[14,32],[1467,1450],{"trials":5700,"activeCount":8},[5701,5705],{"nctId":1583,"briefTitle":1584,"status":56,"phases":5702,"primaryCompletion":75,"completion":103,"start":155,"enrollment":1586,"conditions":5703,"interventions":5704},[41],[1588],[1590,1590,1509,1467],{"nctId":1525,"briefTitle":1526,"status":130,"phases":5706,"primaryCompletion":233,"completion":233,"start":1528,"enrollment":966,"conditions":5707,"interventions":5708},[41],[1530],[1532,1493],{"trials":5710,"activeCount":8},[],{"trials":5712,"activeCount":8},[5713],{"nctId":5714,"briefTitle":5715,"status":56,"phases":5716,"primaryCompletion":1789,"completion":1789,"start":312,"enrollment":5717,"conditions":5718,"interventions":5719},"NCT01100333","GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)",[],2552,[14],[1467],{"intervention":409,"totalTrials":196,"cells":5721},{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5728,"PHASE4":5738,"NA":5740},{"trials":5723,"activeCount":8},[],{"trials":5725,"activeCount":8},[],{"trials":5727,"activeCount":8},[],{"trials":5729,"activeCount":8},[5730,5734],{"nctId":1342,"briefTitle":1343,"status":56,"phases":5731,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":123,"conditions":5732,"interventions":5733},[41],[1348,1349],[1351,409,409,1306],{"nctId":401,"briefTitle":402,"status":56,"phases":5735,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":5736,"interventions":5737},[41],[14],[409,410,390],{"trials":5739,"activeCount":8},[],{"trials":5741,"activeCount":8},[5742],{"nctId":5743,"briefTitle":5744,"status":56,"phases":5745,"primaryCompletion":5746,"completion":5746,"start":5747,"enrollment":5748,"conditions":5749,"interventions":5750},"NCT01416987","A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)",[],"2018-05-10","2011-08-14",600,[14],[409],{"intervention":422,"totalTrials":196,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5767},{"trials":5754,"activeCount":8},[],{"trials":5756,"activeCount":8},[],{"trials":5758,"activeCount":8},[],{"trials":5760,"activeCount":8},[],{"trials":5762,"activeCount":8},[5763],{"nctId":414,"briefTitle":415,"status":56,"phases":5764,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":5765,"interventions":5766},[42],[14],[422,390],{"trials":5768,"activeCount":8},[5769,5775],{"nctId":5770,"briefTitle":5771,"status":130,"phases":5772,"primaryCompletion":2384,"completion":2384,"start":579,"enrollment":5599,"conditions":5773,"interventions":5774},"NCT01100346","Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen",[],[14],[422],{"nctId":5776,"briefTitle":5777,"status":56,"phases":5778,"primaryCompletion":3272,"completion":3272,"start":233,"enrollment":5779,"conditions":5780,"interventions":5782},"NCT01075854","An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)",[],1539,[5781],"Multifollicular Stimulation",[5783],"Gonal-F",{"intervention":5785,"totalTrials":287,"cells":5786},"Interferon beta 1a",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5788,"activeCount":8},[],{"trials":5790,"activeCount":8},[],{"trials":5792,"activeCount":8},[],{"trials":5794,"activeCount":8},[],{"trials":5796,"activeCount":8},[],{"trials":5798,"activeCount":8},[5799,5806],{"nctId":5800,"briefTitle":5801,"status":56,"phases":5802,"primaryCompletion":1238,"completion":1238,"start":1673,"enrollment":5803,"conditions":5804,"interventions":5805},"NCT01142453","An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients",[],231,[3472],[5785],{"nctId":5807,"briefTitle":5808,"status":56,"phases":5809,"primaryCompletion":746,"completion":746,"start":1750,"enrollment":5810,"conditions":5811,"interventions":5812},"NCT01142518","An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone",[],86,[3472],[5785],{"intervention":5814,"totalTrials":287,"cells":5815},"Rebif® New Formulation",{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5822,"PHASE4":5830,"NA":5832},{"trials":5817,"activeCount":8},[],{"trials":5819,"activeCount":8},[],{"trials":5821,"activeCount":8},[],{"trials":5823,"activeCount":8},[5824],{"nctId":5825,"briefTitle":5826,"status":56,"phases":5827,"primaryCompletion":155,"completion":1160,"start":1706,"enrollment":858,"conditions":5828,"interventions":5829},"NCT00441103","A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis",[41],[26],[5814,5814],{"trials":5831,"activeCount":8},[],{"trials":5833,"activeCount":8},[5834],{"nctId":5835,"briefTitle":5836,"status":56,"phases":5837,"primaryCompletion":1216,"completion":1216,"start":1134,"enrollment":5838,"conditions":5839,"interventions":5841},"NCT01080027","Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)",[],254,[5840],"Multiple Sclerosis, Relapsing Remitting",[5814],{"intervention":1180,"totalTrials":287,"cells":5843},{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5854,"PHASE4":5856,"NA":5858},{"trials":5845,"activeCount":8},[],{"trials":5847,"activeCount":8},[],{"trials":5849,"activeCount":8},[5850],{"nctId":1170,"briefTitle":1171,"status":56,"phases":5851,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":5852,"interventions":5853},[40],[1178],[1180,1141,1166,1122,1181],{"trials":5855,"activeCount":8},[],{"trials":5857,"activeCount":8},[],{"trials":5859,"activeCount":8},[5860],{"nctId":5861,"briefTitle":5862,"status":5863,"phases":5864,"conditions":5865,"interventions":5867},"NCT03089658","Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)","APPROVED_FOR_MARKETING",[],[5866],"Metastatic Merkel Cell Carcinoma",[1180],{"intervention":1510,"totalTrials":287,"cells":5869},{"EARLY_PHASE1":5870,"PHASE1":5872,"PHASE2":5874,"PHASE3":5880,"PHASE4":5882,"NA":5884},{"trials":5871,"activeCount":8},[],{"trials":5873,"activeCount":8},[],{"trials":5875,"activeCount":8},[5876],{"nctId":1502,"briefTitle":1503,"status":130,"phases":5877,"primaryCompletion":1472,"completion":1472,"start":1505,"enrollment":179,"conditions":5878,"interventions":5879},[40],[14,32],[1508,1493,1509,1510],{"trials":5881,"activeCount":8},[],{"trials":5883,"activeCount":8},[],{"trials":5885,"activeCount":8},[5886],{"nctId":5500,"briefTitle":5501,"status":56,"phases":5887,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":5506,"conditions":5888,"interventions":5889},[],[5508],[1351,5510,1510],{"intervention":2097,"totalTrials":287,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5898,"PHASE4":5904,"NA":5906},{"trials":5893,"activeCount":8},[],{"trials":5895,"activeCount":8},[],{"trials":5897,"activeCount":8},[],{"trials":5899,"activeCount":8},[5900],{"nctId":2085,"briefTitle":2086,"status":56,"phases":5901,"primaryCompletion":2088,"completion":813,"start":2089,"enrollment":2090,"conditions":5902,"interventions":5903},[41],[2092,2093,2094,1588],[2074,2096,2097],{"trials":5905,"activeCount":8},[],{"trials":5907,"activeCount":8},[5908],{"nctId":5909,"briefTitle":5910,"status":56,"phases":5911,"primaryCompletion":5912,"completion":5912,"start":5913,"enrollment":5914,"conditions":5915,"interventions":5916},"NCT01111084","A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α",[],"2005-06","2004-03",410,[32],[2097],{"intervention":5918,"totalTrials":519,"cells":5919},"Lodoz",{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5924,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5921,"activeCount":8},[],{"trials":5923,"activeCount":8},[],{"trials":5925,"activeCount":8},[],{"trials":5927,"activeCount":8},[],{"trials":5929,"activeCount":8},[],{"trials":5931,"activeCount":8},[5932],{"nctId":5933,"briefTitle":5934,"status":56,"phases":5935,"primaryCompletion":1216,"completion":85,"start":579,"enrollment":5936,"conditions":5937,"interventions":5938},"NCT01080742","An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients",[],1007,[29],[5918],{"intervention":5940,"totalTrials":519,"cells":5941},"recombinant somatropin",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5946,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5943,"activeCount":8},[],{"trials":5945,"activeCount":8},[],{"trials":5947,"activeCount":8},[],{"trials":5949,"activeCount":8},[],{"trials":5951,"activeCount":8},[],{"trials":5953,"activeCount":8},[5954],{"nctId":5955,"briefTitle":5956,"status":56,"phases":5957,"primaryCompletion":5958,"completion":5958,"start":746,"enrollment":2693,"conditions":5959,"interventions":5960},"NCT01082354","A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)",[],"2015-12",[224],[5940],{"intervention":5510,"totalTrials":519,"cells":5962},{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5967,"PHASE3":5969,"PHASE4":5971,"NA":5973},{"trials":5964,"activeCount":8},[],{"trials":5966,"activeCount":8},[],{"trials":5968,"activeCount":8},[],{"trials":5970,"activeCount":8},[],{"trials":5972,"activeCount":8},[],{"trials":5974,"activeCount":8},[5975],{"nctId":5500,"briefTitle":5501,"status":56,"phases":5976,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":5506,"conditions":5977,"interventions":5978},[],[5508],[1351,5510,1510],{"intervention":5980,"totalTrials":519,"cells":5981},"Cetrorelix acetate and Follitropin alfa",{"EARLY_PHASE1":5982,"PHASE1":5984,"PHASE2":5986,"PHASE3":5988,"PHASE4":5990,"NA":5992},{"trials":5983,"activeCount":8},[],{"trials":5985,"activeCount":8},[],{"trials":5987,"activeCount":8},[],{"trials":5989,"activeCount":8},[],{"trials":5991,"activeCount":8},[],{"trials":5993,"activeCount":8},[5994],{"nctId":5995,"briefTitle":5996,"status":56,"phases":5997,"primaryCompletion":4014,"completion":4014,"start":232,"enrollment":5998,"conditions":5999,"interventions":6000},"NCT01109654","An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)",[],2175,[14],[5980],{"intervention":6002,"totalTrials":519,"cells":6003},"Enalapril maleate",{"EARLY_PHASE1":6004,"PHASE1":6006,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":6005,"activeCount":8},[],{"trials":6007,"activeCount":8},[],{"trials":6009,"activeCount":8},[],{"trials":6011,"activeCount":8},[],{"trials":6013,"activeCount":8},[],{"trials":6015,"activeCount":8},[6016],{"nctId":6017,"briefTitle":6018,"status":56,"phases":6019,"primaryCompletion":6020,"completion":6020,"start":1238,"enrollment":6021,"conditions":6022,"interventions":6023},"NCT01074281","An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)",[],"2009-08",2065,[29],[6002],{"intervention":6025,"totalTrials":519,"cells":6026},"Interferon-β-1a",{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6028,"activeCount":8},[],{"trials":6030,"activeCount":8},[],{"trials":6032,"activeCount":8},[],{"trials":6034,"activeCount":8},[],{"trials":6036,"activeCount":8},[],{"trials":6038,"activeCount":8},[6039],{"nctId":6040,"briefTitle":6041,"status":56,"phases":6042,"primaryCompletion":6043,"completion":6043,"start":580,"enrollment":5305,"conditions":6044,"interventions":6045},"NCT01074346","Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis",[],"2011-11",[17],[6025],{"intervention":6047,"totalTrials":519,"cells":6048},"Cetuximab + RT",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6055,"PHASE4":6057,"NA":6059},{"trials":6050,"activeCount":8},[],{"trials":6052,"activeCount":8},[],{"trials":6054,"activeCount":8},[],{"trials":6056,"activeCount":8},[],{"trials":6058,"activeCount":8},[],{"trials":6060,"activeCount":8},[6061],{"nctId":6062,"briefTitle":6063,"status":130,"phases":6064,"primaryCompletion":6065,"completion":5435,"start":6066,"enrollment":1189,"conditions":6067,"interventions":6070},"NCT01303237","A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[],"2013-06-30","2011-02-28",[6068,6069],"Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck","LA SCCHN",[6047],{"intervention":6072,"totalTrials":519,"cells":6073},"Erbitux",{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6078,"PHASE3":6080,"PHASE4":6082,"NA":6084},{"trials":6075,"activeCount":8},[],{"trials":6077,"activeCount":8},[],{"trials":6079,"activeCount":8},[],{"trials":6081,"activeCount":8},[],{"trials":6083,"activeCount":8},[],{"trials":6085,"activeCount":8},[6086],{"nctId":6087,"briefTitle":6088,"status":56,"phases":6089,"primaryCompletion":5452,"completion":5452,"start":233,"enrollment":6090,"conditions":6091,"interventions":6092},"NCT01082315","A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment",[],730,[5360],[6072],{"intervention":6094,"totalTrials":519,"cells":6095},"Recombinant-follicle stimulating hormone",{"EARLY_PHASE1":6096,"PHASE1":6098,"PHASE2":6100,"PHASE3":6102,"PHASE4":6104,"NA":6106},{"trials":6097,"activeCount":8},[],{"trials":6099,"activeCount":8},[],{"trials":6101,"activeCount":8},[],{"trials":6103,"activeCount":8},[],{"trials":6105,"activeCount":8},[],{"trials":6107,"activeCount":8},[6108],{"nctId":6109,"briefTitle":6110,"status":130,"phases":6111,"primaryCompletion":2299,"completion":2299,"start":1160,"enrollment":222,"conditions":6112,"interventions":6113},"NCT01080729","An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen",[],[5781],[6094],{"intervention":6115,"totalTrials":519,"cells":6116},"Prednisone",{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6127},{"trials":6118,"activeCount":8},[],{"trials":6120,"activeCount":8},[],{"trials":6122,"activeCount":8},[],{"trials":6124,"activeCount":8},[],{"trials":6126,"activeCount":8},[],{"trials":6128,"activeCount":8},[6129],{"nctId":6130,"briefTitle":6131,"status":56,"phases":6132,"primaryCompletion":2384,"completion":104,"start":233,"enrollment":6133,"conditions":6134,"interventions":6136},"NCT01075711","Determine the Improvement in Activity Status\u002FQuality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)",[],2728,[6135],"Arthritis, Rheumatoid",[6115],{"intervention":6138,"totalTrials":519,"cells":6139},"No Intervention",{"EARLY_PHASE1":6140,"PHASE1":6142,"PHASE2":6144,"PHASE3":6146,"PHASE4":6148,"NA":6150},{"trials":6141,"activeCount":8},[],{"trials":6143,"activeCount":8},[],{"trials":6145,"activeCount":8},[],{"trials":6147,"activeCount":8},[],{"trials":6149,"activeCount":8},[],{"trials":6151,"activeCount":8},[6152],{"nctId":6153,"briefTitle":6154,"status":56,"phases":6155,"primaryCompletion":6156,"completion":6156,"start":6157,"enrollment":6158,"conditions":6159,"interventions":6160},"NCT02889380","A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment",[],"2017-04-26","2016-08-29",3000,[14],[6138],{"intervention":6162,"totalTrials":519,"cells":6163},"Bisoprolol or bisoprolol + HCTZ",{"EARLY_PHASE1":6164,"PHASE1":6166,"PHASE2":6168,"PHASE3":6170,"PHASE4":6172,"NA":6174},{"trials":6165,"activeCount":8},[],{"trials":6167,"activeCount":8},[],{"trials":6169,"activeCount":8},[],{"trials":6171,"activeCount":8},[],{"trials":6173,"activeCount":8},[],{"trials":6175,"activeCount":8},[6176],{"nctId":6177,"briefTitle":6178,"status":56,"phases":6179,"primaryCompletion":4014,"completion":4014,"start":311,"enrollment":6180,"conditions":6181,"interventions":6182},"NCT01109043","Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate",[],351,[29],[6162]]